WO2023223317A1 - Self-assembling dendrimers and antibacterial uses thereof - Google Patents
Self-assembling dendrimers and antibacterial uses thereof Download PDFInfo
- Publication number
- WO2023223317A1 WO2023223317A1 PCT/IL2023/050499 IL2023050499W WO2023223317A1 WO 2023223317 A1 WO2023223317 A1 WO 2023223317A1 IL 2023050499 W IL2023050499 W IL 2023050499W WO 2023223317 A1 WO2023223317 A1 WO 2023223317A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dendrimer
- pharmaceutical composition
- dendrimers
- bacteria
- formula
- Prior art date
Links
- 239000000412 dendrimer Substances 0.000 title claims abstract description 471
- 229920000736 dendritic polymer Polymers 0.000 title claims abstract description 468
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 79
- 239000002245 particle Substances 0.000 claims abstract description 163
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 108
- 229920000962 poly(amidoamine) Polymers 0.000 claims abstract description 102
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 98
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 98
- 239000000203 mixture Substances 0.000 claims abstract description 98
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 65
- 208000015181 infectious disease Diseases 0.000 claims abstract description 50
- 230000001775 anti-pathogenic effect Effects 0.000 claims abstract description 45
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 39
- 230000002209 hydrophobic effect Effects 0.000 claims description 167
- 239000008194 pharmaceutical composition Substances 0.000 claims description 107
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 106
- 241000894006 Bacteria Species 0.000 claims description 105
- 125000003342 alkenyl group Chemical group 0.000 claims description 92
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 59
- 150000001412 amines Chemical group 0.000 claims description 56
- 229960003405 ciprofloxacin Drugs 0.000 claims description 53
- 229960004099 azithromycin Drugs 0.000 claims description 47
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 47
- 229960003722 doxycycline Drugs 0.000 claims description 46
- 241000191967 Staphylococcus aureus Species 0.000 claims description 38
- 239000013543 active substance Substances 0.000 claims description 36
- 229960003276 erythromycin Drugs 0.000 claims description 32
- 108010059993 Vancomycin Proteins 0.000 claims description 30
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 30
- 229960003165 vancomycin Drugs 0.000 claims description 30
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 30
- 229960001668 cefuroxime Drugs 0.000 claims description 27
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 27
- 230000002195 synergetic effect Effects 0.000 claims description 27
- 241000589968 Borrelia Species 0.000 claims description 21
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 20
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 20
- 241000568336 Borreliella bavariensis Species 0.000 claims description 19
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 19
- 239000003937 drug carrier Substances 0.000 claims description 19
- 229960003085 meticillin Drugs 0.000 claims description 19
- 241000588748 Klebsiella Species 0.000 claims description 18
- 241000589516 Pseudomonas Species 0.000 claims description 18
- 241000191940 Staphylococcus Species 0.000 claims description 18
- 241000588650 Neisseria meningitidis Species 0.000 claims description 17
- 241000588653 Neisseria Species 0.000 claims description 13
- 208000016604 Lyme disease Diseases 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 150000003141 primary amines Chemical class 0.000 claims description 10
- 230000003115 biocidal effect Effects 0.000 claims description 9
- 150000001993 dienes Chemical class 0.000 claims description 9
- 150000003512 tertiary amines Chemical class 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 6
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 20
- SENLDUJVTGGYIH-UHFFFAOYSA-N n-(2-aminoethyl)-3-[[3-(2-aminoethylamino)-3-oxopropyl]-[2-[bis[3-(2-aminoethylamino)-3-oxopropyl]amino]ethyl]amino]propanamide Chemical compound NCCNC(=O)CCN(CCC(=O)NCCN)CCN(CCC(=O)NCCN)CCC(=O)NCCN SENLDUJVTGGYIH-UHFFFAOYSA-N 0.000 abstract description 6
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 44
- 239000003814 drug Substances 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 37
- 230000001580 bacterial effect Effects 0.000 description 34
- 239000012528 membrane Substances 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 29
- 229940079593 drug Drugs 0.000 description 29
- 239000000243 solution Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 229910001868 water Inorganic materials 0.000 description 20
- 230000009467 reduction Effects 0.000 description 18
- 125000005647 linker group Chemical group 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 239000002105 nanoparticle Substances 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 241000192125 Firmicutes Species 0.000 description 15
- 229940088710 antibiotic agent Drugs 0.000 description 14
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- -1 cyclic amine Chemical class 0.000 description 13
- 238000000502 dialysis Methods 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 239000004098 Tetracycline Substances 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 235000019364 tetracycline Nutrition 0.000 description 12
- 150000003522 tetracyclines Chemical class 0.000 description 12
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 229960003376 levofloxacin Drugs 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 108010013198 Daptomycin Proteins 0.000 description 10
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 10
- 229960005484 daptomycin Drugs 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 229960002626 clarithromycin Drugs 0.000 description 9
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 9
- 229960004089 tigecycline Drugs 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 8
- 229960002180 tetracycline Drugs 0.000 description 8
- 229930101283 tetracycline Natural products 0.000 description 8
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 7
- 108010001478 Bacitracin Proteins 0.000 description 7
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 7
- 108010078777 Colistin Proteins 0.000 description 7
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 7
- 229930182566 Gentamicin Natural products 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- ZBJNZFQKYZCUJU-PAHFEQBRSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O ZBJNZFQKYZCUJU-PAHFEQBRSA-N 0.000 description 7
- 229930193140 Neomycin Natural products 0.000 description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 7
- 108010053950 Teicoplanin Proteins 0.000 description 7
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 7
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 7
- 229960004821 amikacin Drugs 0.000 description 7
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 7
- 229960003071 bacitracin Drugs 0.000 description 7
- 229930184125 bacitracin Natural products 0.000 description 7
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical group O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 7
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 7
- 229960005091 chloramphenicol Drugs 0.000 description 7
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 7
- 229940090805 clavulanate Drugs 0.000 description 7
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 7
- 229960002227 clindamycin Drugs 0.000 description 7
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 7
- 229960003346 colistin Drugs 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 229960000308 fosfomycin Drugs 0.000 description 7
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 7
- 229960002518 gentamicin Drugs 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 229960002182 imipenem Drugs 0.000 description 7
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 229960000318 kanamycin Drugs 0.000 description 7
- 229930027917 kanamycin Natural products 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 229930182823 kanamycin A Natural products 0.000 description 7
- 229960003907 linezolid Drugs 0.000 description 7
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 7
- 229960002260 meropenem Drugs 0.000 description 7
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 7
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 7
- 229960003702 moxifloxacin Drugs 0.000 description 7
- 229960003128 mupirocin Drugs 0.000 description 7
- 229930187697 mupirocin Natural products 0.000 description 7
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 7
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 7
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 7
- 229960000515 nafcillin Drugs 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 229960004927 neomycin Drugs 0.000 description 7
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 7
- 229960000564 nitrofurantoin Drugs 0.000 description 7
- 229960001180 norfloxacin Drugs 0.000 description 7
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 7
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 7
- 229960001019 oxacillin Drugs 0.000 description 7
- 229940056360 penicillin g Drugs 0.000 description 7
- 229960002292 piperacillin Drugs 0.000 description 7
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 7
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 7
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 7
- 229960005266 polymyxin b Drugs 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 7
- 229960000885 rifabutin Drugs 0.000 description 7
- 229960001225 rifampicin Drugs 0.000 description 7
- 229960005322 streptomycin Drugs 0.000 description 7
- 229960005404 sulfamethoxazole Drugs 0.000 description 7
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 7
- 229960001608 teicoplanin Drugs 0.000 description 7
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 7
- 229960003250 telithromycin Drugs 0.000 description 7
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 7
- 229960004659 ticarcillin Drugs 0.000 description 7
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 7
- 229960001082 trimethoprim Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000028161 membrane depolarization Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 229930186147 Cephalosporin Natural products 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229940124587 cephalosporin Drugs 0.000 description 5
- 150000001780 cephalosporins Chemical class 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 150000002148 esters Chemical group 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 229940124307 fluoroquinolone Drugs 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000003120 macrolide antibiotic agent Substances 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000004626 scanning electron microscopy Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 4
- 208000031729 Bacteremia Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000001301 anti-borrelial effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 230000009881 electrostatic interaction Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 4
- 229960003923 gatifloxacin Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 229940041033 macrolides Drugs 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 229940040944 tetracyclines Drugs 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- GDEURKKLNUGTDA-UHFFFAOYSA-M (2z)-3-propyl-2-[(2z,4z)-5-(3-propyl-1,3-benzothiazol-3-ium-2-yl)penta-2,4-dienylidene]-1,3-benzothiazole;iodide Chemical compound [I-].S1C2=CC=CC=C2[N+](CCC)=C1/C=C/C=C/C=C1N(CCC)C2=CC=CC=C2S1 GDEURKKLNUGTDA-UHFFFAOYSA-M 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- XQVWYOYUZDUNRW-UHFFFAOYSA-N N-Phenyl-1-naphthylamine Chemical compound C=1C=CC2=CC=CC=C2C=1NC1=CC=CC=C1 XQVWYOYUZDUNRW-UHFFFAOYSA-N 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000003917 TEM image Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 229940126575 aminoglycoside Drugs 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 150000002960 penicillins Chemical class 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 150000007660 quinolones Chemical class 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229960000707 tobramycin Drugs 0.000 description 3
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000589902 Leptospira Species 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010052057 Neuroborreliosis Diseases 0.000 description 2
- 239000004100 Oxytetracycline Substances 0.000 description 2
- 101150026476 PAO1 gene Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 230000000658 anti-neisserial effect Effects 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 229940125687 antiparasitic agent Drugs 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229940041011 carbapenems Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960004261 cefotaxime Drugs 0.000 description 2
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 2
- 229960005090 cefpodoxime Drugs 0.000 description 2
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229960002398 demeclocycline Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000002897 diene group Chemical group 0.000 description 2
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 2
- 229960004100 dirithromycin Drugs 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940041028 lincosamides Drugs 0.000 description 2
- AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 description 2
- 229960004196 lymecycline Drugs 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940042016 methacycline Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229940041009 monobactams Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960000625 oxytetracycline Drugs 0.000 description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 2
- 235000019366 oxytetracycline Nutrition 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960005224 roxithromycin Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 2
- 229960004954 sparfloxacin Drugs 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000000733 zeta-potential measurement Methods 0.000 description 2
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- FCTALLDRCBVIQN-UHFFFAOYSA-N 1,1'-biphenyl;naphthalen-1-amine Chemical compound C1=CC=C2C(N)=CC=CC2=C1.C1=CC=CC=C1C1=CC=CC=C1 FCTALLDRCBVIQN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000606646 Anaplasma Species 0.000 description 1
- 241001135163 Arcobacter Species 0.000 description 1
- 241001061225 Arcos Species 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241001136161 Avibacterium Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241001148534 Brachyspira Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589994 Campylobacter sp. Species 0.000 description 1
- 241000068542 Candidatus Piscichlamydia Species 0.000 description 1
- 241000190890 Capnocytophaga Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000611330 Chryseobacterium Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000186249 Corynebacterium sp. Species 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 241000605056 Cytophaga Species 0.000 description 1
- 241000606006 Dichelobacter Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000607473 Edwardsiella <enterobacteria> Species 0.000 description 1
- 241000605314 Ehrlichia Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 241000012732 Gallibacterium Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241001581234 Histophilus Species 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000579706 Kytococcus Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241001469654 Lawsonia <weevil> Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001293415 Mannheimia Species 0.000 description 1
- 241000604449 Megasphaera Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241001212279 Neisseriales Species 0.000 description 1
- 241001468109 Neorickettsia Species 0.000 description 1
- 241000409939 Nicoletella Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241001135630 Ornithobacterium Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000607568 Photobacterium Species 0.000 description 1
- 241000192127 Piscirickettsia Species 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 239000012095 PrestoBlue reagent Substances 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241001240958 Pseudomonas aeruginosa PAO1 Species 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241001478225 Riemerella Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000589973 Spirochaeta Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000823609 Staphylococcus aureus subsp. aureus RN4220 Species 0.000 description 1
- 241001478878 Streptobacillus Species 0.000 description 1
- 241001478880 Streptobacillus moniliformis Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 241001496920 Tenacibaculum Species 0.000 description 1
- 208000004374 Tick Bites Diseases 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
- 241000460694 Trueperella Species 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000011482 antibacterial activity assay Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- SVWLIIFHXFGESG-UHFFFAOYSA-N formic acid;methanol Chemical compound OC.OC=O SVWLIIFHXFGESG-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000028744 lysogeny Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- RDZTWEVXRGYCFV-UHFFFAOYSA-M sodium 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonate Chemical compound [Na+].OCCN1CCN(CCS([O-])(=O)=O)CC1 RDZTWEVXRGYCFV-UHFFFAOYSA-M 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000011806 swiss nude mouse Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/02—Polyamines
- C08G73/028—Polyamidoamines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides use of amphiphilic amine-terminated poly(amidoamine) (PAMAM) dendrimers and bola-amphiphilic amine-terminated PAMAM dendrimer and particles formed by said dendrimers as antipathogenic agents. Specifically, antibacterial use of compositions comprising these dendrimers is presented. Provided also particles formed by said dendrimers encapsulating antibacterial agents and use of such loaded particles for treatments of pathogenic infections such as bacterial infections.
Description
SELF-ASSEMBLING DENDRIMERS AND ANTIBACTERIAL USES THEREOF
FIELD OF THE INVENTION
The present invention is in the field of bacterial infections and relates to the use of self-assembling amphiphilic poly(amidoamine) amine (PAMAM) dendrimers, and particles thereof encapsulating antibacterial agents, as antibacterial agents.
BACKGROUND OF THE INVENTION
Antibacterial resistance has become a global threat, as drug resistance makes bacterial infection increasing and difficult to treat. This pressing public health problem is driving development of new antibacterial agents to overcome drug resistance, which includes modification of existing antibiotics, identification of active agents with novel targets against resistant bacteria, and elaboration of antimicrobial peptides with dual antibacterial and immunomodulatory activities, just to name a few. Among these, new antibacterial agents which are substantially different from conventional antibiotics are of peculiar interest and in urgent need in order to confront the increasingly alarming antibacterial resistance. In this context, amphiphilic antibacterial agents are particularly appealing because they mimic the antibacterial feature of natural antimicrobial peptides and antibacterial detergents. In addition, amphiphilic compounds may self-assemble into supramolecular structures which can also contribute to the antibacterial activity via cooperative and multivalent interaction. Consequently, a myriad of amphiphilic molecules has been established as antibacterial candidates.
Dendrimers are a unique family of synthetic molecules with precisely controlled radial architecture and special multivalent cooperativity confined within a small three-dimensional volume. Different dendrimers have been studied for their antimicrobial activity (Mintzer MA, et al., Mol Pharm. 2012, 9(3), 342-54; Castonguay A et al., New J. Chem., 2012, 36, 199-204. doi.org/10.1039/C 1NJ2048 IE; Alfei et al., Nanomaterials 2020 ;10(10):2022. doi: 10.3390/nano 10102022; Alfei and Caviglia Pharmaceutics 2022, 14(10), 2016). Among them, the poly(amidoamine) (PAMAM) dendrimers are of special interest by virtue of their excellent biocompatibility owing to peptide-mimicry (Lyu et al., in “Dendrimer Chemistry: Synthetic Approaches Towards Complex Architectures”, Eds: Michal Malkoch, Sandra Garcia Gallego, Royal Society Chemistry, 2020, 85-113) However, active dendrimers are often high-generation molecules bearing charged terminals associated with considerable cytotoxicity. Recently, small amphiphilic dendrimers composed of hydrophobic entities and
hydrophilic dendrons have been explored for antibacterial activity, where their activity was frequently related to dendrimer generation, terminal charge, and hydrophilicity/hydrophobicity balance (Meyers et al., J Am Chem Soc 2008;130:14444-5; Kannan et al., ACS Appl Bio Mater 2019;2:3212-24).
There is still an unmet need for potent and safe antibacterial compounds having novel modes of action and capable of providing effective treatment of bacterial infections.
SUMMARY OF THE INVENTION
The present invention is based on an observation that certain amphiphilic dendrimers comprising a long hydrophobic chain and a small hydrophilic PAMAM dendron and having a positive zeta potential demonstrated an antibacterial activity. The observation demonstrates that not only the charge, but also the charge density and steric size associated with the terminal functionalities and self-assembling feature of the amphiphilic dendrimers, play a crucial role in their antibacterial activity. In particular, the amine-terminated dendrimer denoted la exhibits the most potent antibacterial activity against both Gram-positive and Gram-negative bacteria as well as drug-resistant bacteria, and shows biofilm eradication. Surprisingly, according to the present invention, dendrimers of low generation having a relatively low number of terminal amines provide a profound antibacterial activity. Such dendrimers are easy and inexpensive to manufacture and due to their relatively low molecular weight, they have a high chance to be effective upon administration. Interestingly, adding double-bound bonds to the lipophilic tail provided new antibacterial properties. Such, compounds having double bonds showed high activity against Borrelia bavariensis and Neisseria meningitidis, which was hard to obtain for by most of the dendrimers with a saturated hydrophobic tail. It is also demonstrated that aside antibacterial activity of the dendrimers of the present invention, they may be used for encapsulation of other antibacterial compounds and provide additive and even synergistic antibacterial effect. As an example, azithromycin (AZM), doxycycline (DOX), and ciprofloxacin (CIP) were encapsulated in micelles formed by dendrimer la. The resulted encapsulated structures provided an outstanding and even synergistic antibacterial activity.
According to one aspect, the present invention provides a composition comprising, as an active agent, a dendrimer selected from an amine-terminated, poly(amidoamine) (PAMAM) dendrimer comprising a hydrophobic tail and bola-amphiphilic amine- terminated PAMAM dendrimer, for use in treating a pathogenic infection. According to some examples, the pathogenic infection is a bacterial infection. According to some
examples, the dendrimers are selected from generation 2, 3 or 4 dendrimers. According to certain examples, the terminal amine is a positively charged amine. According to some examples, the terminal amine is a primary amine. According to some examples, the hydrophobic tail comprises a C16-C32 alkyl. According to some examples, the dendrimer has a structure of Formula I:
X is a C16-C32 straight alkyl.
According to some examples, X is a C18 straight alkyl. According to some examples, R is o o . According to some examples, X is a C18 alkyl and R is
H H
According to some embodiments, the dendrimers have a structure selected from Formula II, III, IV, V, VI, VII, VIII, IX, X, and XI, as described below. According to some examples, the dendrimer is a bola-amphiphilic amine-terminated polyamidoamine dendrimer. According to other examples, the dendrimer has a structure selected from Formula XII, XIII, XIV, as described below
According to any one of the above examples, the composition is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient.
According to another aspect, the present invention provides a hydrophobic antipathogenic agent encapsulated within a dendrimer of the present invention. According to some examples the antipathogenic agent is an antibacterial agent. Thus, according to some examples, the present invention provides a hydrophobic antibacterial agent encapsulated within an amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail. According to some embodiments, the dendrimers and encapsulated hydrophobic antibacterial agent form particles, i.e., loaded particles.
According to some embodiments, the hydrophobic antibacterial agent is selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime. According to some embodiments, the dendrimer has a structure selected from Formula II, III, IV, V, VI, VII, VIII, IX, X and XI and the hydrophobic antibacterial agent is selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime. according to some embodiments, the loaded particles of the present invention have a synergistic antibacterial activity of the dendrimer and the loaded agent. According to some embodiments, the pharmaceutical composition comprising loaded particles of the present invention comprises dendrimers and loaded agents having synergistic antibacterial activity.
According to some embodiments, the pharmaceutical composition of the present invention comprising the loaded particles is for use in treating a pathogenic, such as bacterial, infection.
According to another aspect, the present invention provides a method of treating a pathogenic, e.g. bacterial, infection in a subject in need thereof comprising administering to said subject an effective amount of amphiphilic poly(amidoamine) (PAMAM) amine- terminated dendrimers comprising a hydrophobic tail as described in any one of the above and below examples.
According to yet another aspect, the present invention provides an amine-terminated polyamidoamine dendrimer comprising a hydrophobic tail, wherein the hydrophobic tail comprises a C16-C32 alkenyl. According to some examples, the amine-terminated polyamidoamine dendrimer has a structure of Formula V, VI, VII or VIII, as described herein. According to some embodiments, the present invention provides particles formed by such dendrimers. According to some embodiments, the particles further encapsulate a hydrophobic active agent. According to some embodiments, the active agent is an antibacterial agent. According to some examples, the present invention provides a composition, such as a pharmaceutical composition, comprising said dendrimers or said particles. According to some embodiments, the composition is for use in treating a bacterial infection.
According to a further aspect, the present invention provides a bola-amphiphilic amine-terminated polyamidoamine dendrimer, wherein the terminal amine is a tertiary amine. According to some examples, the amine-terminated polyamidoamine dendrimer has a structure of Formula XII, XIII, or XIV, as described herein. According to some embodiments, the present invention provides particles formed by such dendrimers. According to some embodiments, the particles further encapsulate a hydrophobic active
agent. According to some embodiments, the active agent is an antibacterial agent. According to some examples, the present invention provides a composition, such as a pharmaceutical composition, comprising said dendrimers or said particles. According to some embodiments, the composition is for use in treating a bacterial infection.
According to certain aspects, the present invention provides a method of treating a bacterial infection in a subject in need thereof comprising administering to said subject the pharmaceutical composition comprising loaded particles comprising the dendrimers of the present invention and a hydrophobic antibacterial agent.
BRIEF DESCRIPTION OF DRAWINGS
Figs. 1A-1D show the dendrimers la-d and their preparations. Fig. 1A - scheme of synthesis of the dendrimers la-d starting with the common dendrimer 1; Fig IB - general scheme of all 4 structures; Fig 1C - the structure of dendrimer la; Fig. ID - the structure of dendrimer lb; Fig. ID - the structure of 1st generation NFL-terminated dendrimer; Fig. IE - the structure of 2st generation NFL-terminated dendrimer; Fig. IF the structure of dendrimer DDC18-4TA; Fig. 1G - the structure of dendrimer DD4TA; Figs. 1H-1K the structure of dendrimer comprising one or more double bonds in the hydrophobic tail denoted as DD01e8A, DD01e8TA, DDLin8A and DDLin8TA, respectively; Fig. IL - a bola- amphiphilic dendrimer denoted as JCB4A; and Fig IM - a bola- amphiphilic dendrimer denoted as MBola-8T; and Fig. IN - a bola- amphiphilic dendrimer denoted as JCB8A.
Fig. 2 shows transmission electron microscopy (TEM) images of the supramolecular nanomicelles formed by dendrimers la (Fig. 2A), lb (Fig. 2B), 1c (Fig. 2C) and Id (Fig. 2D). Size distribution for the nanomicelles of dendrimers la-d measured using TEM. For each sample, at least 300 particles in different TEM images were randomly selected and measured by using ImageJ software to calculate the size distribution of the nanomicelles.
Fig. 3 shows cytotoxicity of dendrimers la-d in mouse fibroblast (L929) cells and human embryonic kidney 293 (HEK293) cells. Cell viability was measured in triplicate using the PrestoBlue assay.
Figs. 4A-4D show imaging of live and dead bacteria cells and their membrane integrity and morphology. Fluorescent microscopic imaging of live and dead cells of (Fig. 4A) E. coli and (Fig. 4B) S. m//' s7Mcthicillin -resistant S. aureus (MRS A) upon treatment with la. Live and dead cells were stained using SYTO9 (green) and propidium iodide (PI) (red), respectively. Fig. 4C and Fig. 4D show scanning electron microscopic imaging of E. coli and S. aureus MRS , respectively, upon treatment with la. Fig. 4E shows hemolysis data
of dendrimers la-d in mouse red blood cells (RBC’s); Fig. 4E shows inhibition of biofilm formation of S. aureus JLA513 by dendrimer la. The biofilm viability after 24 hr incubation of the different treatments was measured by the tetrazolium dye MTT assay. Results present the mean (± SEM) of 3 independent experiments. Dendrimer 2 was used as negative control. Figs. 5A-5C show the permeability of the bacterial outer membrane (OM) in E. coli (Fig. 5A) and depolarization of the inner membrane (IM) in E. coli (Fig. 5B) and MRSA (Fig. 5C) after treatment with la was evaluated using the N-phenyl-1 -naphthylamine (NPN) dye and the 3,3 '-dipropylthiadicarbocyanine iodide (diSC3(5)) probe, respectively.
Fig. 6 shows the chemical structure of the dendron 2 having no hydrophobic alkyl chain. Figs. 7A and 7B show the chemical structure of 1st (Fig. 7A) and 2nd (Fig. 7B) generation of dendrimer la.
DETAILED DESCRIPTION OF THE INVENTION
The present application is based on an unexpected observation that low-generation amine-terminated dendrimer comprising a hydrophobic tail showed strong and broad antibacterial activity. As shown in the Examples, amine-terminated dendrimer shows high antibacterial activity and low cytotoxicity. In addition, it was shown that antibiotics encapsulated within nanoparticles formed by such dendrimers provided an extended and, in some cases, a synergistic antibacterial activity.
According to one aspect, the present invention provides a composition comprising, as an active agent, a dendrimer selected from a polyamidoamine (PAMAM) dendrimer comprising a hydrophobic tail or a bola- amphiphilic PAMAM dendrimer, for use in treating a pathogenic infection. According to some embodiments, the dendrimer is an amine- terminated dendrimer. According to some embodiments, the present invention provides a composition comprising, as an active agent, an amine-terminated poly(amidoamine) (PAMAM) dendrimer comprising a hydrophobic tail, for use in treating a pathogenic infection. According to any one of the embodiments and aspects of the present invention, the dendrimers are amphiphilic. According to some embodiments of the application, the pharmaceutical composition comprises a plurality of the dendrimers. According to some embodiments, the pathogenic infection is a bacterial infection and the dendrimers of the present invention act as antibacterial active agent. Thus, the present invention provides a composition comprising, as an active agent, an amine-terminated amphiphilic poly(amidoamine) (PAMAM) dendrimers comprising a hydrophobic tail, for use in treating a bacterial infection.
The term “pathogenic infection” as used herein refers to a disease or infection caused by disease-causing microorganisms having a cell membrane and/or wall, their multiplication and the reaction of body tissues to these microorganisms and the toxins that they produce. The term “pathogenic infection” includes but are not limited to infections by bacteria, parasites, protozoans and fungi. According to some embodiments, the pathogenic infection is a bacterial infection. Thus, according to some embodiments, the present invention provides a composition comprising as an active agent an amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail, for use in treating a bacterial infection.
According to some embodiments, the pathogenic infection is a parasitic infection. According to some embodiments, the pathogenic infection is a fungal infection.
The term dendrimer refers to a molecule having a core and multiple shells of branched structures extending from the core. Dendron is a part of a dendrimer with branches coming from a central point and means a wedge-shaped dendrimer fraction having a plurality of surface functional groups and a central functional group. For both a dendrimer and a dendron, the branches can be connected to the core directly or through a linker. A dendrimer generally includes multiple shells or generations, such as Gl, G2, G3, G4, and so on. Repeated response chains are often used to add each generation to the dendrimer.
The PAMAM dendrimers of the present invention have amine terminations and can be any generation of dendrimers including, but not limited to, generation 1 PAMAM dendrimers, generation 2 PAMAM dendrimers, generation 3 PAMAM dendrimers, generation 4 PAMAM dendrimers, generation 5 PAMAM dendrimers. According to some embodiments, the dendrimers of the present invention are low-generation dendrimers.
According to some embodiments, the dendrimer is selected from a generation 2, 3 or 4 dendrimer. According to some embodiments, the dendrimer is G2 dendrimer. According to another embodiment, the dendrimer is G3 dendrimer. According to another embodiment, the dendrimer is G4 or G5 dendrimer. The generation number defines the number of terminal amines in the dendrimer. According to some embodiments, the dendrimer comprises 4 terminal amines. According to some embodiments, the dendrimer comprises 8 terminal amines. According to some embodiments, the dendrimer comprises 16 terminal amines. According to some embodiments, the dendrimer comprises 32 terminal amines. According to some embodiments, the dendrimer comprises 64 terminal amines. According to some embodiments, the dendrimer comprises 4, 8, 16 or 32 terminal amines.
According to some embodiments, the amines of the dendrimer terminus are primary amines. According to another embodiment, the terminal amines are secondary amines. According to yet another embodiment, the terminal amines are tertiary amines. According to some embodiments, the terminal amines are positively charged at neutral and acidic pH. According to some embodiments, the terminal amine is a cyclic amine. According to some embodiment, the terminal amines are amidine.
According to some embodiments, the active agent is an amine-terminated polyamidoamine dendrimer comprising a hydrophobic tail. Thus, according to some embodiments, the present invention provides a pharmaceutical composition comprising, as an active agent, an amine-terminated polyamidoamine dendrimer comprising a hydrophobic tail, for use in treating a pathogenic infection. According to some embodiments, the dendrimers of the present invention have a positive surface charge, leading to charged zeta potential of the self-assembled nanoparticles. Specifically, zeta potential is the charge that develops at the interface between a solid surface and its liquid medium. According to some embodiments, the zeta potential of the dendrimers of the present invention is from +1 to +80 mV, from 5 to 60 mV, or from 10 to 50 mV. According to some embodiments, the zeta potential of the dendrimers is from 20 to 45 mV. Zeta potential may be measured e.g., as defined in Examples.
The term "hydrophobic tail" refers to any group having low water solubility and containing four or more carbon atoms. Examples of such hydrophobic tails are aliphatic and aromatic hydrocarbons. The term “hydrophobic tail” encompasses also a saturated or unsaturated, substituted or unsubstituted, straight or branched, cyclic or acyclic hydrocarbon group. As used herein, the term "hydrophobic tail" refers to an aliphatic tail bound to the core of the dendrimer.
According to some embodiments, the hydrophobic tail is an alkyl. As used herein, the term “alkyl”, “alkyl group”, or “alkylene” means a linear or branched, saturated hydrocarbon including one or more carbon atoms (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more carbon atoms), which is optionally substituted. The notation “Cl 6-24 alkyl” means an optionally substituted linear or branched, saturated hydrocarbon including 16-24 carbon atoms. Unless otherwise specified, an alkyl group described herein refers to both unsubstituted and substituted alkyl groups. According to some embodiments, the hydrophobic tail comprises an alkyl having 10 to 60 carbon atoms. According to some embodiments, the tail comprises a straight alkyl comparing 12 to 40 carbon atoms.
According to some embodiments, the hydrophobic tail comprises a C16-C32 alkyl. According to some embodiments, the hydrophobic tail comprises a C16-28 alkyl. According to some embodiments, the hydrophobic tail comprises a C16-C22 alkyl. According to some embodiments, the alkyl is a straight alkyl. According to some embodiments, the hydrophobic tail comprises a C16-C22 straight alkyl. According to some embodiments, the hydrophobic tail is a C16 alkyl. According to some embodiments, the hydrophobic tail is a C18 alkyl. According to some embodiments, the hydrophobic tail is a C20 alkyl. According to some embodiments, the hydrophobic tail is a C22 alkyl.
According to another embodiment, the alkyl is a branched alkyl. According to some embodiments, each chain branch of the branched alkyl comprises 10-20 carbons. According to some embodiments, at least one branch of the branched alky comprises 14 or more carbons. According to some embodiments, at least one branch of the branched alky comprises 16 or more carbons.
According to some embodiments, the hydrophobic tail is an alkenyl. As used herein, the term “alkenyl”, “alkenyl group”, or “alkenylene” means a linear or branched hydrocarbon including two or more carbon atoms (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more carbon atoms) and at least one double bond, which is optionally substituted. The notation “C 16-22 alkenyl” means an optionally substituted linear or branched hydrocarbon including 16-22 carbon atoms and at least one carbon-carbon double bond. An alkenyl group may include one, two, three, four, or more carbon-carbon double bonds. For example, C18 alkenyl may include one or more double bonds. A C18 alkenyl group including two double bonds may be a linoleyl group. Unless otherwise specified, an alkenyl group described herein refers to both unsubstituted and substituted alkenyl groups.
According to some embodiments, the tail comprises a straight alkenyl comparing 12 to 40 carbon atoms. According to some embodiments, the hydrophobic tail comprises a C16- C32 alkenyl. According to some embodiments, the hydrophobic tail comprises a C16-C32 alkenyl. According to some embodiments, the hydrophobic tail comprises a C16-C28 alkenyl. According to some embodiments, the hydrophobic tail is a C16 alkenyl. According to some embodiments, the hydrophobic tail is a C18 alkenyl. According to some embodiments, the hydrophobic tail is a C20 alkenyl. According to some embodiments, the hydrophobic tail is a C22 alkenyl. According to some embodiments, the alkenyl is a straight alkenyl. According to some embodiments, the hydrophobic tail comprises a C16-C22 straight alkenyl. According to another embodiment, the alkenyl is a branched alkenyl.
According to some embodiments, each chain branch of the branched alkenyl comprises 10- 20 carbons. According to some embodiments, at least one branch of the branched alkenyl comprises 14 or more carbons. According to some embodiments, at least one branch of the branched alkenyl comprises 16 or more carbons. According to some embodiments, at least one branch of the branched alkenyl comprises 18 or more carbons. According to some embodiments, at least one branch of the branched alkenyl comprises 20 carbons. According to some embodiments, one of the branches is an alkenyl and one or more other branches is an alkyl.
According to certain embodiments, the hydrophobic chain is a C16-C32 alkynyl. As used herein, the term “alkynyl”, “alkynyl group”, or “alkynylene” means a linear or branched hydrocarbon including two or more carbon atoms (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more carbon atoms) and at least one carbon-carbon triple bond, which is optionally substituted.
According to some embodiments, the hydrophobic tail is bound to the dendrimer via a linker such as a cyclic, aromatic or non-aromatic compound. According to some embodiments, the linker comprises a triazole or a derivative thereof. According to some embodiments, the linker is an ester, amide, or disulfide. According to some embodiments, the hydrophobic tail is bound to the core of the dendrimer.
According to some embodiments, the present invention provides a composition comprising, as an active agent, an amphiphilic poly(amidoamine) (PAMAM) amine- terminated dendrimer comprising a hydrophobic tail, for use in treating a bacterial infection, wherein the dendrimers are selected from generation 2, 3 or 4 dendrimers comprising from 4 to 16 terminal amines and the hydrophobic tail is a moiety selected from a C16-C32 alkyl and a C16-C32 alkenyl. According to some embodiments, the alkyl or alkenyl are straight. According to some embodiments, the terminal amines of the dendrimers are primary amines. According to some embodiments, the terminal amines of the dendrimers are secondary amines. According to some embodiments, the terminal amines of the dendrimers are tertiary amines.
According to some embodiments, the dendrimer of the present invention has a structure of Formula I:
H H H combination thereof, and X is a C12-C40 alkyl or alkenyl. According to some embodiment,
X is selected from C12, C14, C16, C18, C20, C22, C24, C26, C28, C30, C32, C34, C36 and
C38 alkyl. According to some embodiments, X is a C14-C32 alkyl. According to some embodiments, X is a C16-C24 alkyl. According to some embodiments, X is a C16-C24 alkenyl. According to some embodiments, X is a C16-C22 alkyl. According to some embodiments, X is C18 alkyl. According to some embodiments, X is a straight alkyl. According to some embodiments, X is a branched alkyl. According to some embodiment, X is selected from C12, C14, C16, C18, C20, C22, C24, C26, C28, C30, C32, C34, C36 and C38 alkenyl. According to some embodiments, X is a C14-C32 alkenyl. According to some embodiments, X is a C16-C24 alkenyl. According to some embodiments, X is a C16-C22 alkenyl. According to some embodiments, X is C18 alkenyl. According to some embodiments, the alkenyl comprises two double bonds, i.e., a diene. According to some embodiments, the double bonds are conjugated double bonds. According to some embodiments, the alkenyl comprises 3, 4 or 5 double bonds. According to some embodiments, X is a straight, unbranched alkenyl or alkyl.
According to some embodiments, X is C18 alkyl. According to other embodiments, X is C 18 alkenyl. 0
According to some embodiments, R is
. According to another embodiment, R is
According to yet another embodiment, X is C18 straight
H H H
According to some embodiments, R does not comprise guanidine.
According to one embodiment, the dendrimer has a structure of Formula IX:
According to one embodiment, the dendrimer has a structure of Formula X:
According to some embodiments, the present invention provides a composition comprising dendrimers having a structure selected from a structure of Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, and any combination thereof, for use in treating a pathogenic infection. According to some embodiments, the present invention provides a composition comprising dendrimers having a structure selected from a structure of Formula I, II, III, IV, V, VI, VII, VIII, IX, X and XI, for use in treating a bacterial infection. According to some embodiments, the present invention provides a composition comprising dendrimers having a structure of Formula II, for use in treating a bacterial infection. According to some embodiments, the present invention provides a composition comprising dendrimers having a structure of Formula III, for use in treating a bacterial infection. According to some
embodiments, the present invention provides a composition comprising dendrimers having a structure of Formula IV, for use in treating a bacterial infection. According to some embodiments, the present invention provides a composition comprising dendrimers having a structure of Formula V, for use in treating a bacterial infection. According to some embodiments, the present invention provides a composition comprising dendrimers having a structure of Formula VI, for use in treating a bacterial infection. According to some embodiments, the present invention provides a composition comprising dendrimers having a structure of Formula VII, for use in treating a bacterial infection. According to some embodiments, the present invention provides a composition comprising dendrimers having a structure of Formula VIII, for use in treating a bacterial infection. According to some embodiments, the present invention provides a composition comprising dendrimers having a structure of Formula IX, for use in treating a bacterial infection. According to some embodiments, the present invention provides a composition comprising dendrimers having a structure of Formula X, for use in treating a bacterial infection. According to some embodiments, the present invention provides a composition comprising dendrimers having a structure of Formula XI, for use in treating a bacterial infection. According to any one of the above embodiments, the use is for treating a parasitic infection. According to any one of the above embodiments, the use is for treating a fungal infection.
According to any one of the above embodiments, the dendrimers of the present invention are capable of self-assembling and forming particles. Thus, according to any one of the above embodiments, the present invention provides a composition comprising a plurality of particles formed by the dendrimers according to any one of the above embodiments, for use in treating bacterial infection. According to some embodiments, the size of the particles is from 5 to 100 nm, from 7 to 75, from 10 to 50 or from 5 to 50 nm. According to other embodiments, the size of the particles is from 7 to 35 nm. According to some embodiments, the nanoparticles have an average size of from 8 to 40 nm. According to some embodiments, the nanoparticles have an average size of from 10 to 35 nm. According to some embodiments, the nanoparticles have an average size of from 10 to 30 nm. According to some embodiments, the nanoparticles have an average size of from 8 to 30 nm. According to some embodiments, the nanoparticles have an average size of from 10 to 25 nm.
According to some embodiments, the dendrimer is bola- amphiphilic amine-terminated polyamidoamine dendrimer. Therefore, the present invention provides a pharmaceutical
composition comprising, as an active agent, bola- amphiphilic amine-terminated polyamidoamine dendrimer, for use in treating a pathogenic infection.
The term "bola- amphiphilic dendrimer" refers to molecules that have two PAMAM dendrons connected via a long hydrophobic hydrocarbon chain. According to some embodiments, the bola- amphiphilic amine-terminated polyamidoamine dendrimer has a structure of Z-Y-Z, wherein Z has the structure of Formula I:
wherein R is selected from ■ ■> and any
combination thereof, and X is a moiety selected from C8-C16 alkyl, Cl l alkyl, C8-C16 alkenyl and C 11 alkenyl and Y is a linker.
According to some embodiments, the linker has a structure L f J . According to some embodiments, the linker is a di-sulfide moiery.
According to some embodiments, the bola-amphiphilic amine-terminated poly amidoamine dendrimer has Formula XII
According to some embodiments, the bola-amphiphilic amine-terminated poly amidoamine dendrimer has Formula XIII (Fig. IM):
According to some embodiments, the bola-amphiphilic amine-terminated poly amidoamine dendrimer has Formula XIV (Fig. IN)
According to any one of the above embodiments, the minimal minimum inhibitory concentration to inhibit 90 % of bacteria (MIC) of the dendrimers of the present invention or of particles formed by said dendrimers is from 0.1 to 100 pM, from 0.5 to 50 pM, from 1 to 50 pM or from 1 to 10 pM. According to any one of the above embodiments, the MIC of the dendrimers of the present invention or of particles formed by said dendrimers is from 20 to 70 pM or from 40 to 60 pM.
According to any one of the above embodiments, the pathogenic infection is a bacterial infection. According to some embodiments, the bacterial infection is caused by bacteria selected from Gram-positive and Gram-negative bacteria. According to some embodiments, the composition is for use in treating bacterial infection caused by Gram-positive bacteria. According to some embodiments, the composition is for use in treating bacterial infection caused by Gram-negative bacteria.
The term "infection" or "bacterial infection" as used herein refers to and includes the presence of bacteria, in or on a subject, which, if its growth were inhibited, would result in a benefit to the subject. As such, the term "infection" in addition to referring to the presence of bacteria also refers to normal flora, which is not desirable. The term "infection" includes infections caused by bacteria.
The term “Gram-positive” refers to bacteria that are stained dark blue or violet by Gram staining (crystal violet), in contrast to Gram-negative bacteria which cannot retain the crystal violet stain and instead take up the counterstain (safranin or fuchsine) thus appearing red or pink. Gram-positive organisms are able to retain the crystal violet stain because of a higher amount of peptidoglycan in the inner cell wall and typically lack the secondary or outer wall and lipopolysaccharide layer found in Gram-negative bacteria.
According to some embodiments, Gram-negative bacteria is selected from the group consisting of Actinobacillus, Aeromonas, Anaplasma, Arcobacter, Avibacterium, Bacteroides, Bartonella, Bordetella, Borrelia, Brachyspira, Brucella, Campylobacter, Capnocytophaga, Chlamydia, Chlamydophila, Chryseobacterium, Coxiella, Cytophaga, Dichelobacter, Edwardsiella, Ehrlichia, Escherichia, Flavobacterium, Francisella, Fusobacterium, Gallibacterium, Haemophilus, Histophilus, Klebsiella, Lawsonia, Leptospira, Mannheimia, Megasphaera, Moraxella, Neorickettsia, Nicoletella, Neisseria, Ornithobacterium, Pasteurella, Photobacterium, Piscichlamydia, Piscirickettsia, Porphyromonas, Prevotella, Proteus, Pseudomonas, Rickettsia, Riemerella, Salmonella, Streptobacillus, Tenacibaculum, Vibrio and Yersinia.
According to some embodiments, the Gram-positive bacteria is selected from Staphylococcus spp, Streptococci, Enterococcus spp, Leuconostoc spp, Corynebacterium spp, Arcanobacteria spp, Trueperella spp, Rhodococcus spp, Bacillus spp, Anaerobic Cocci, Anaerobic Gram-Positive Nonsporulating Bacilli, Actinomyces spp, Clostridium spp, Nocardia spp, Erysipelothrix spp, Eisteria spp, Kytococcus spp, Mycoplasma spp, Ureaplasma spp, Borrelia spp and Mycobacterium spp.
Examples of infectious bacteria include Helicobacter pyloris, Borelia burgdorferi, Legionella pneumophilia, Mycobacteria spp. (e.g., M. tuberculosis, M. avium, M. intracellulare, M. kansasii, M. gordonae). Neisseria gonorrhoeae, Listeria monocytogenes, Streptococcus pyogenes (Group A Streptococcus), Streptococcus agalactiae (Group B Streptococcus), Streptococcus (viridans group), Streptococcus faecalis, Streptococcus Bovis, Streptococcus (anaerobic spp.), Streptococcus pneumoniae, pathogenic Campylobacter sp., Enterococcus sp., Haemophilus influenzae, Bacillus anthracis, Corynebacterium diphtheriae, Corynebacterium sp., Erysipelothrix rhusiopathiae, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, Bacteroides sp., Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidum, Treponema pertenue, Leptospira, and Actinomyces israelii.
According to some embodiments, the composition of the present invention is for use in treating Pseudomonas bacteria, such as Pseudomonas aeruginosa. According to some embodiments, the composition of the present invention is for treating Staphylococcus bacteria, such as Staphylococcus aureus. According to some embodiments, the composition of the present invention is for treating Klebsiella bacteria, such as Klebsiella pneumoniae. According to some embodiments, the composition of the present invention is for treating Borrelia bacteria, such as Borrelia bavariensis. According to some embodiments, the composition of the present invention is for treating Neisseria bacteria, such as Neisseria meningitidis. According to some embodiments, the composition of the present invention is for treating drug resistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA).
According to some embodiments, the composition of the present invention is for use in treating a bacterial infection, provided that the infection is not caused by Borrelia and/or Neisseria.
According to some embodiments, the present invention provides a dendrimer of
Formula II for use in treating a bacterial infection caused by Gram-positive bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula II for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula III for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula III for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula IV for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula IV for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula V for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula V for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula VI for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula VI for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula VII for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula
VII for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula VIII for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula
VIII for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula IX for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula IX for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula X for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula X for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula XI for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula XI for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula XII for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula
XII for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula XIII for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula
XIII for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the present invention provides a dendrimer of Formula XIV for use in treating a bacterial infection caused by Gram-positive bacteria. According to some embodiments, the present invention provides a dendrimer of Formula
XIV for use in treating a bacterial infection caused by Gram-negative bacteria.
According to some embodiments, the composition of the present invention comprising the dendrimer of Formula II is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae and drugresistant bacteria such as methicillin resistant Staphylococcus aureus (MRS A). According to some embodiments, the composition of the present invention comprising the dendrimer of Formula III is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae and drugresistant bacteria such as methicillin resistant Staphylococcus aureus (MRS A). According to some embodiments, the composition of the present invention comprising the dendrimer of Formula IV is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae, drug-resistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA), Borrelia bacteria, such as Borrelia bavariensis and Neisseria bacteria, such as Neisseria meningitidis. According to some embodiments, the composition of the present invention comprising the dendrimer of Formula V is for treating a bacterial infection caused by a bacteria selected
from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae, drugresistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA), and Borrelia bacteria, such as Borrelia bavariensis. According to some embodiments, the composition of the present invention comprising the dendrimer of Formula VI is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae, drug-resistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA), and Borrelia bacteria, such as Borrelia bavariensis. According to some embodiments, the composition of the present invention comprising the dendrimer of Formula VII is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae, drugresistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA), and Borrelia bacteria, such as Borrelia bavariensis. According to some embodiments, the composition of the present invention comprising the dendrimer of Formula VIII is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae, drug-resistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA), and Borrelia bacteria, such as Borrelia bavariensis. According to some embodiments, the composition of the present invention comprising the dendrimer of Formula IX is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae and drugresistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA). According to some embodiments, the composition of the present invention comprising the dendrimer of Formula X is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae and drugresistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA). According to some embodiments, the composition of the present invention comprising the dendrimer of Formula XI is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae, drug-resistant
bacteria such as methicillin resistant Staphylococcus aureus (MRSA), Borrelia bacteria, such as Borrelia bavariensis and Neisseria bacteria, such as Neisseria meningitidis. According to some embodiments, the composition of the present invention comprising the dendrimer of Formula XII is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae and drugresistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA). According to some embodiments, the composition of the present invention comprising the dendrimer of Formula XIII is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae and drugresistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA). According to some embodiments, the composition of the present invention comprising the dendrimer of Formula XIV is for treating a bacterial infection caused by a bacteria selected from Pseudomonas bacteria, such as Pseudomonas aeruginosa, Staphylococcus bacteria, such as Staphylococcus aureus, Klebsiella bacteria, such as Klebsiella pneumoniae and drugresistant bacteria such as methicillin resistant Staphylococcus aureus (MRSA).
According to some embodiments, the composition of the present invention comprising the dendrimer of Formula V is for treating a bacterial infection caused by a bacteria selected from Borrelia bacteria, such as Borrelia bavariensis and Neisseria bacteria, such as Neisseria meningitidis. According to some embodiments, the composition of the present invention comprising the dendrimer of Formula VI is for treating a bacterial infection caused by a bacteria selected from Borrelia bacteria, such as Borrelia bavariensis and Neisseria bacteria, such as Neisseria meningitidis. According to some embodiments, the composition of the present invention comprising the dendrimer of Formula VII is for treating a bacterial infection caused by a bacteria selected from Borrelia bacteria, such as Borrelia bavariensis and Neisseria bacteria, such as Neisseria meningitidis. According to some embodiments, the composition of the present invention comprising the dendrimer of Formula VIII is for treating a bacterial infection caused by a bacteria selected from Borrelia bacteria, such as Borrelia bavariensis and Neisseria bacteria, such as Neisseria meningitidis. According to some embodiments, the composition of the present invention comprising the dendrimer of Formula IV is for treating a bacterial infection caused by a bacteria selected from Borrelia bacteria, such as Borrelia bavariensis and Neisseria bacteria, such as Neisseria meningitidis.
According to some embodiments, the composition of the present invention comprising the dendrimer of Formula XII is for treating a bacterial infection caused by Borrelia bacteria, such as Borrelia bavariensis.
According to any one of the above embodiments, the composition of the present invention is for treating parasitic infections. According to any one of the above embodiments, the composition of the present invention is for treating fungal infections.
The term “treating” a condition or patient refers to taking steps to obtain beneficial or desired results, including clinical results. Beneficial or desired clinical results include, but are not limited to, or ameliorating, abrogating, substantially inhibiting, slowing or reversing the progression of a disease, condition or disorder, substantially ameliorating or alleviating clinical or esthetical symptoms of a condition, substantially preventing the appearance of clinical or esthetical symptoms of a disease, condition, or disorder, and protecting from harmful or annoying symptoms. Treating further refers to accomplishing one or more of the following: (a) reducing the severity of the disorder; (b) limiting development of symptoms characteristic of the disorder(s) being treated; (c) limiting worsening of symptoms characteristic of the disorder(s) being treated; (d) limiting recurrence of the disorder(s) in patients that have previously had the disorder(s); and/or (e) limiting recurrence of symptoms in patients that were previously asymptomatic for the disorder(s). The term "treat", "treating" or "treatment" includes both prophylactic and therapeutic purposes. The term "prophylactic treatment" refers to treating a subject who is not yet infected, but who is susceptible to, or otherwise at a risk of infection (preventing the bacterial infection).
According to any one of the above embodiments, the composition of the present invention comprises a carrier. The term “carrier” includes as a class any compound or composition useful in facilitating storage, stability, administration, cell targeting and/or delivery of the topical composition, including, without limitation, suitable vehicles, skin conditioning agents, skin protectants, diluents, emollients, solvents, excipients, pH modifiers, salts, colorants, rheology modifiers, thickeners, lubricants, humectants, antifoaming agents, erodeable polymers, hydrogels, surfactants, emulsifiers, emulsion stabilizers, adjuvants, surfactants, preservatives, chelating agents, fatty acids, mono-di- and tri-glycerides and derivates thereof, waxes, oils and water.
According to any one of the above embodiments, the composition of the present invention is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier. Therefore, according to any one of the above embodiments, the term "composition" encompasses and may be replaced by the term "pharmaceutical composition". Thus,
according to any one of the above embodiments, the present invention provides a pharmaceutical composition comprising as an active agent an amphiphilic PAMAM amine- terminated dendrimer comprising a hydrophobic tail and a pharmaceutically acceptable carrier, for use in treating a pathogenic infection such as a bacterial infection. According to any one of the above embodiments, the present invention provides a pharmaceutical composition comprising as an active agent a bola-amphiphilic amine-terminated PAMAM dendrimer a pharmaceutically acceptable carrier, for use in treating a pathogenic infection such as a bacterial infection. Any one of the above embodiments apply herein as well.
The term “pharmaceutical composition” as used herein refers to a composition comprising at least one active agent as disclosed herein formulated together with one or more pharmaceutically acceptable carriers.
Formulation of the pharmaceutical composition may be adjusted according to applications. In particular, the pharmaceutical composition may be formulated using a method known in the art so as to provide a rapid, continuous or delayed release of the active ingredient after administration to mammals. For example, the formulation may be any one selected from among plasters, granules, lotions, liniments, lemonades, aromatic waters, powders, syrups, ophthalmic ointments, liquids and solutions, aerosols, extracts, elixirs, ointments, fluidextracts, emulsions, suspensions, decoctions, infusions, ophthalmic solutions, tablets, suppositories, injections, spirits, capsules, creams, troches, tinctures, pastes, pills, and soft or hard gelatin capsules.
The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" as used herein refers to any and all solvents, dispersion media, preservatives, antioxidants, coatings, isotonic and absorption delaying agents, surfactants, fillers, disintegrants, binders, diluents, lubricants, glidants, pH adjusting agents, buffering agents, enhancers, wetting agents, solubilizing agents, surfactants, antioxidants the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may contain other active compounds providing supplemental, additional, or enhanced therapeutic functions, solid carriers or excipients such as, for example, lactose, starch or talcum or liquid carriers such as, for example, water, fatty oils or liquid paraffins.
Solutions or suspensions used for parenteral, intradermal, or subcutaneous application typically include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol (or other
synthetic solvents), antibacterial agents (e.g., benzyl alcohol, methyl parabens), antioxidants (e.g., ascorbic acid, sodium bisulfite), chelating agents (e.g., ethylenediaminetetraacetic acid), buffers (e.g., acetates, citrates, phosphates), and agents that adjust tonicity (e.g., sodium chloride, dextrose). The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide, for example. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose glass or plastic vials.
Pharmaceutical compositions adapted for parenteral administration include, but are not limited to, aqueous and non-aqueous sterile injectable solutions or suspensions, which can contain antioxidants, buffers, bacteriostats and solutes that render the compositions substantially isotonic with the blood of an intended recipient. Such compositions can also comprise water, alcohols, polyols, glycerine and vegetable oils, for example. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules and tablets. Such compositions preferably comprise a therapeutically effective amount of a compound of the invention and/or other therapeutic agent(s), together with a suitable amount of carrier to provide the form for proper administration to the subject.
The composition for oral administration may be in a form of tablets, troches, lozenges, aqueous, or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Pharmaceutical compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and may further comprise one or more agents selected from sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active agent in admixture with nontoxic pharmaceutically acceptable excipients, which are suitable for the manufacture of tablets. These excipients may be, e.g., inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrating agents, e.g., com starch or alginic acid; binders; and lubricating agents. The tablets are preferably coated utilizing known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide an extended release of the drug over a longer period.
The composition of the present invention may be administered by any known method. The term "administering” or “administration of’ a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art. For example, a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitonealy, intravenously, subcutaneously, ocularly,
sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin duct). A compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow or controlled release of the compound or agent. Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods. According to some embodiments, the composition is administered 1, 2, 3, 4, 5 or 6 times a day. According to other embodiments, the composition is administered 1, 2, 3, 4, 5 or 6 times a month. In some embodiments, the administration includes both direct administration, including selfadministration, and indirect administration, including the act of prescribing a drug. For example, as used herein, a physician who instructs a patient to self-administer a drug, or to have the drug administered by another and/or who provides a patient with a prescription for a drug is administering the drug to the patient. According to some embodiments, the composition, e.g. a pharmaceutical composition, is administered orally. According to some embodiments, the composition, e.g. a pharmaceutical composition, is administered via injections, e.g. by IV infusion.
The composition of the present invention may be co-administered with any other anti- pathogenic agent. The term "co-administration" of the compounds is performed in a regimen selected from a single combined composition, separate individual compositions administered substantially at the same time, and separate individual compositions administered under separate schedules and include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time. The compounds can be administered sequentially in either order or substantially simultaneously. The term “sequential manner” refers to an administration of two compounds at different times, and optionally in different modes of administration. The agents can be administered sequentially in either order.
The term “substantially simultaneous manner” refers to the administration of two compounds with only a short time interval between them. In some embodiments, the time interval is in the range of from 0.5 to 60 minutes.
In some embodiments, the anti-pathogenic agent is an antibacterial agent. The term "anti-pathogenic agent" as used herein refers to any substance, compound or a combination of substances or a combination of compounds capable of: (i) inhibiting, reducing or preventing the growth of a pathogen; (ii) inhibiting or reducing the ability of a pathogen to produce infection in a subject; or (iii) inhibiting or reducing the ability of a pathogen to
multiply or remain infective in the environment. The composition of the present invention may be co-administered with any other antibacterial agent. The term "antibacterial agent" as used herein refers to any substance, compound or a combination of substances or a combination of compounds capable of: (i) inhibiting, reducing or preventing growth of bacteria; (ii) inhibiting or reducing the ability of a bacteria to produce infection in a subject; or (iii) inhibiting or reducing the ability of bacteria to multiply or remain infective in the environment. The term "antibacterial agent" also refers to a compound capable of decreasing infectivity or virulence of bacteria.
According to some embodiments, the present invention provides a composition for use in treating a bacterial infection as described in any one of the above embodiments, wherein the use comprises co-administering the composition with an additional antibacterial agent. According to some embodiments, the additional antibacterial agent is selected from aminoglycosides, carbacephems, carbapenems, cephalosporins, cephamycins, fluoroquinolones, glycopeptides, lincosamides, macrolides, monobactams, penicillins, quinolones, sulfonamides, and tetracyclines. According to some embodiments, the additional antibacterial agent is selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime. According to some embodiments, the additional antibacterial agent is selected from rifampin, vancomycin, erythromycin, clarithromycin, azithromycin, tetracycline, doxycycline, chloramphenicol, clindamycin, linezolid, ciprofloxacin, levofloxacin, norfloxacin, moxifloxacin, gentamicin, amikacin, kanamycin, neomycin, streptomycin, polymyxin b, daptomycin, fosfomycin, imipenem, meropenem, nafcillin, oxacillin, penicillin g, piperacillin, ticarcillin, trimethoprim, sulfamethoxazole, rifabutin, colistin, teicoplanin, telithromycin, tigecycline, mupirocin, bacitracin, nitrofurantoin, and clavulanate. According to some embodiments, the co-administration provides a synergistic antibacterial effect.
According to another aspect, the present invention provides a method for treating a pathogenic infection in a subject in need thereof comprising administering to said subject a therapeutically effective amount of amphiphilic poly(amidoamine) (PAMAM) amine - terminated dendrimers comprising a hydrophobic tail or bola-amphiphilic amine-terminated polyamidoamine dendrimer, or a pharmaceutical composition thereof as described in any one of the above aspects and embodiments. All terms, embodiments and definitions disclosed in any one of the above aspects apply and are encompassed herein as well.
According to some embodiments, the pathogenic infection is a bacterial infection.
The term “therapeutically effective amount” of a drug or agent is an amount of a drug or an agent that, when administered to a subject will have the intended therapeutic effect, e.g. antibacterial effect, such as bacteriostatic or bactericidic effect. The full therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations. The precise effective amount needed for a subject will depend upon, for example, the subject's size, health and age, the nature and extent of the cognitive impairment, and the therapeutics or combination of therapeutics selected for administration, and the mode of administration. The skilled person can readily determine the effective amount for a given situation by routine experimentation.
According to another aspect, the present invention provides use of poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail or of bola- amphiphilic amine-terminated polyamidoamine dendrimers in preparation of a medicament for treating a pathogenic, such as bacterial, infection. All terms, embodiments and definitions disclosed in any one of the above aspects apply and are encompassed herein as well.
According to another aspect, the present invention provides a pharmaceutical composition comprising a hydrophobic anti -pathogenic agent encapsulated within an amine- terminated poly(amidoamine) (PAMAM) dendrimer comprising a hydrophobic tail. According to any one of the above and below embodiments, the dendrimers are amphiphilic. All terms, embodiments and definitions disclosed in any one of the above aspects apply and are encompassed herein as well. The dendrimers of the present invention form particles that encapsulate/entrap the hydrophobic anti-pathogenic agent. Thus, the present invention provides a pharmaceutical composition comprising a plurality of particles, formed by an amine-terminated PAMAM dendrimer comprising a hydrophobic tail, encapsulating a hydrophobic anti-pathogenic agent. According to some embodiments, the anti -pathogenic agent is an antibacterial agent. Thus, according to some embodiments, the present invention provides a pharmaceutical composition comprising a hydrophobic antibacterial agent encapsulated within amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail. According to some embodiments, the antibacterial agent and dendrimers encapsulating said agent form particles, referred to as “loaded particles”. Thus, according to some embodiments, the present invention provides a pharmaceutical composition comprises a plurality of particles comprising a hydrophobic antibacterial agent encapsulated within amphiphilic poly (amidoamine) (PAMAM) amine- terminated dendrimers comprising a hydrophobic tail. In other words, the present invention
provides a pharmaceutical composition comprising a plurality of particles formed by amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail loaded with/encapsulating a hydrophobic antibacterial agent. According to some embodiments, the anti -pathogenic agent is an anti-parasitic agent.
According to some embodiment, the dendrimers are as described in any one of the above aspects and embodiments. According to some embodiments, the dendrimers are selected from a generation 2, 3 or 4 dendrimers. According to some embodiments, the dendrimer comprises 4, 8, 16 or 32 terminal amines. According to some embodiments, the terminal amine is selected from a primary, secondary and tertiary amine. According to some embodiments, the amine is a positively charged amine. According to some embodiments, the wherein hydrophobic tail comprises a C16-C32 or C16-C24 alkyl or alkenyl.
According to some embodiments, the dendrimer has a structure of formula I:
wherein R is selected from , and any
n H > combination thereof, X is a C16-C32 alkyl or alkenyl. According to some embodiments, X is a straight alkyl. According to some embodiments, X is C16-C22 alkyl. According to some embodiment, X is selected from C12, C14, C16, C18, C20, C22, C24, C26, C28, C30, C32, C34, C36 and C38 alkyl. According to some embodiments, X is a C14-C32 alkyl. According to some embodiments, X is a C16-C24 alkyl. According to some embodiments, X is a C16- C24 alkenyl. According to some embodiments, X is a C16-C22 alkyl. According to some embodiments, X is C18 alkyl. According to some embodiments, X is a straight alkyl. According to some embodiments, X is a branched alkyl. According to some embodiment, X is selected from C12, C14, C16, C18, C20, C22, C24, C26, C28, C30, C32, C34, C36 and C38 alkenyl. According to some embodiments, X is a C14-C32 alkenyl. According to some embodiments, X is a C16-C24 alkenyl. According to some embodiments, X is a C16-C22
alkenyl. According to some embodiments, X is C18 alkenyl. According to some embodiments, the alkenyl comprises two double bonds, i.e., a diene. According to some embodiments, the double bonds are conjugated double bonds. According to some embodiments, the alkenyl comprises 3, 4 or 5 double bonds. According to some embodiments, X is a straight, unbranched alkenyl or alkyl.
According to some embodiments, X is C18 alkyl. According to some embodiments, X o is C 18 alkenyl According to some embodiments, R is
According to another embodiments, X is C 18 straight alkyl and R is
H
According to some embodiments, the antipathogenic agent is an antibacterial agent.
According to some embodiments, the antibacterial agent is hydrophobic. According to some embodiments, the pharmaceutical composition comprises a hydrophobic antibacterial agent encapsulated within particles obtained upon self-assembling of the dendrimers of the present invention. According to some embodiments, the dendrimers are selected from dendrimers having the structure selected from Formula II, III, IV, V, VI, VII, VIII, IX, X, XI and any combination thereof. According to some embodiment, the dendrimer has a structure as defined in Fig. 1. According to some embodiments, the present invention provides a pharmaceutical composition comprising a hydrophobic anti-pathogenic agent, such as an antibacterial agent, encapsulated within particles formed by dendrimers having the structure of Formula II, and a pharmaceutically acceptable carrier. According to some embodiments, the present invention provides a pharmaceutical composition comprising a hydrophobic antipathogenic agent, such as an antibacterial agent, encapsulated within particles formed by dendrimers having the structure of Formula III, and a pharmaceutically acceptable carrier. According to some embodiments, the present invention provides a pharmaceutical composition comprising a hydrophobic anti -pathogenic agent, such as an antibacterial agent, encapsulated within particles formed by dendrimers having the structure of Formula IV, and a pharmaceutically acceptable carrier. According to some embodiments, the present invention provides a pharmaceutical composition comprising a hydrophobic anti-pathogenic agent, such as an antibacterial agent, encapsulated within particles formed by dendrimers having the structure of Formula V, and a pharmaceutically acceptable carrier. According to some embodiments, the present invention provides a pharmaceutical composition
comprising a hydrophobic anti-pathogenic agent, such as an antibacterial agent, encapsulated within particles formed by dendrimers having the structure of Formula VI, and a pharmaceutically acceptable carrier. According to some embodiments, the present invention provides a pharmaceutical composition comprising a hydrophobic anti-pathogenic agent, such as an antibacterial agent, encapsulated within particles formed by dendrimers having the structure of Formula VII, and a pharmaceutically acceptable carrier. According to some embodiments, the present invention provides a pharmaceutical composition comprising a hydrophobic anti-pathogenic agent, such as an antibacterial agent, encapsulated within particles formed by dendrimers having the structure of Formula VIII, and a pharmaceutically acceptable carrier. According to some embodiments, the present invention provides a pharmaceutical composition comprising a hydrophobic anti-pathogenic agent, such as an antibacterial agent, encapsulated within particles formed by dendrimers having the structure of Formula IX, and a pharmaceutically acceptable carrier. According to some embodiments, the present invention provides a pharmaceutical composition comprising a hydrophobic anti-pathogenic agent, such as an antibacterial agent, encapsulated within particles formed by dendrimers having the structure of Formula X, and a pharmaceutically acceptable carrier. According to some embodiments, the present invention provides a pharmaceutical composition comprising a hydrophobic anti-pathogenic agent, such as an antibacterial agent, encapsulated within particles formed by dendrimers having the structure of Formula XI, and a pharmaceutically acceptable carrier.
According to some embodiments, the hydrophobic antibacterial agent is selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime.
According to some embodiments, the hydrophobic antibacterial agent is selected from hydrophobic aminoglycosides, hydrophobic carbacephems, hydrophobic carbapenems, hydrophobic cephalosporins, hydrophobic cephamycins, hydrophobic fluoroquinolones, hydrophobic glycopeptides, hydrophobic lincosamides, hydrophobic macrolides, monobactams, hydrophobic penicillins, hydrophobic quinolones, hydrophobic sulfonamides, and hydrophobic tetracyclines. According to some embodiments, the hydrophobic antibacterial agent is selected from hydrophobic aminoglycosides, hydrophobic cephalosporins, hydrophobic fluoroquinolones, hydrophobic macrolides, hydrophobic penicillins, hydrophobic quinolones, and hydrophobic tetracyclines. In some examples, tetracycline is selected from doxycycline, minocycline, demeclocycline, oxytetracycline, lymecycline and methacycline. In some examples, the fluoroquinolone is selected ciprofloxacin, levofloxacin, levofloxacin, gatifloxacin, gatifloxacin and sparfloxacin. In
some macrolide is selected from azithromycin, clarithromycin, dirithromycin, or roxithromycin. In some examples, cephalosporin is selected from cefuroxime, cefpodoxime, cefotaxime, ceftriaxone and ceftazidime.
Compositions comprising these particles are formulated and tested for their antibacterial activity.
According to some embodiments, the hydrophobic antibacterial agent is selected from rifampin, vancomycin, erythromycin, clarithromycin, azithromycin, tetracycline, doxycycline, chloramphenicol, clindamycin, linezolid, ciprofloxacin, levofloxacin, norfloxacin, moxifloxacin, gentamicin, amikacin, kanamycin, neomycin, streptomycin, polymyxin b, daptomycin, fosfomycin, imipenem, meropenem, nafcillin, oxacillin, penicillin g, piperacillin, ticarcillin, trimethoprim, sulfamethoxazole, rifabutin, colistin, teicoplanin, telithromycin, tigecycline, mupirocin, bacitracin, nitrofurantoin, and clavulanate.
According to some embodiments, the loaded particles comprise dendrimers of Formula II encapsulating an antibacterial agent selected from rifampin, vancomycin, erythromycin, clarithromycin, azithromycin, tetracycline, doxycycline, chloramphenicol, clindamycin, linezolid, ciprofloxacin, levofloxacin, norfloxacin, moxifloxacin, gentamicin, amikacin, kanamycin, neomycin, streptomycin, polymyxin b, daptomycin, fosfomycin, imipenem, meropenem, nafcillin, oxacillin, penicillin g, piperacillin, ticarcillin, trimethoprim, sulfamethoxazole, rifabutin, colistin, teicoplanin, telithromycin, tigecycline, mupirocin, bacitracin, nitrofurantoin, and clavulanate. According to some embodiments, the loaded particles comprise dendrimers of Formula II encapsulating azithromycin. According to some embodiments, the loaded particles comprise dendrimers of Formula II encapsulating ciprofloxacin. According to some embodiments, the loaded particles comprise dendrimers of Formula II encapsulating vancomycin. According to some embodiments, the loaded particles comprise dendrimers of Formula II encapsulating cefuroxime. According to some embodiments, the loaded particles comprise dendrimers of Formula II encapsulating azithromycin. According to some embodiments, the loaded particles comprise dendrimers of Formula II encapsulating doxycycline. According to some embodiments, the loaded particles comprise dendrimers of Formula II encapsulating erythromycin.
According to some embodiments, the loaded particles comprise dendrimers of Formula III encapsulating an antibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime. According to some embodiments, the loaded particles comprise dendrimers of Formula III encapsulating an antibacterial agent
selected from rifampin, vancomycin, erythromycin, clarithromycin, azithromycin, tetracycline, doxycycline, chloramphenicol, clindamycin, linezolid, ciprofloxacin, levofloxacin, norfloxacin, moxifloxacin, gentamicin, amikacin, kanamycin, neomycin, streptomycin, polymyxin b, daptomycin, fosfomycin, imipenem, meropenem, nafcillin, oxacillin, penicillin g, piperacillin, ticarcillin, trimethoprim, sulfamethoxazole, rifabutin, colistin, teicoplanin, telithromycin, tigecycline, mupirocin, bacitracin, nitrofurantoin, and clavulanate. According to some embodiments, the loaded particles comprise dendrimers of According to some embodiments, the loaded particles comprise dendrimers of Formula IV encapsulating an antibacterial agent selected from rifampin, vancomycin, erythromycin, clarithromycin, azithromycin, tetracycline, doxycycline, chloramphenicol, clindamycin, linezolid, ciprofloxacin, levofloxacin, norfloxacin, moxifloxacin, gentamicin, amikacin, kanamycin, neomycin, streptomycin, polymyxin b, daptomycin, fosfomycin, imipenem, meropenem, nafcillin, oxacillin, penicillin g, piperacillin, ticarcillin, trimethoprim, sulfamethoxazole, rifabutin, colistin, teicoplanin, telithromycin, tigecycline, mupirocin, bacitracin, nitrofurantoin, and clavulanate. According to some embodiments, the loaded particles comprise dendrimers of Formula IV encapsulating an antibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime. According to some embodiments, the loaded particles comprise dendrimers of Formula IV encapsulating an antibacterial agent ciprofloxacin. According to some embodiments, the loaded particles comprise dendrimers of Formula IV encapsulating an antibacterial agent doxycycline. According to some embodiments, the loaded particles comprise dendrimers of Formula V encapsulating an antibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime. According to some embodiments, the loaded particles comprise dendrimers of Formula VI encapsulating an antibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime. According to some embodiments, the loaded particles comprise dendrimers of Formula VII encapsulating an antibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime. According to some embodiments, the loaded particles comprise dendrimers of Formula VIII encapsulating an antibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime. According to some embodiments, the loaded particles comprise dendrimers of Formula IX encapsulating an antibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime. According to some embodiments, the loaded particles comprise dendrimers of Formula X encapsulating an
antibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime. According to some embodiments, the loaded particles comprise dendrimers of Formula XI encapsulating an antibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime.
According to some embodiments, the loaded particles comprise dendrimers of Formula II, III, IV, V, VI, VII, VIII, IX, X, or XI encapsulating an antibacterial agent selected from rifampin, vancomycin, erythromycin, clarithromycin, azithromycin, tetracycline, doxycycline, chloramphenicol, clindamycin, linezolid, ciprofloxacin, levofloxacin, norfloxacin, moxifloxacin, gentamicin, amikacin, kanamycin, neomycin, streptomycin, polymyxin b, daptomycin, fosfomycin, imipenem, meropenem, nafcillin, oxacillin, penicillin g, piperacillin, ticarcillin, trimethoprim, sulfamethoxazole, rifabutin, colistin, teicoplanin, telithromycin, tigecycline, mupirocin, bacitracin, nitrofurantoin, and clavulanate.
According to some embodiments, the antipathogenic agent is an anti-parasitic agent. According to some embodiments, the antipathogenic agent is an anti-fungal agent.
According to any one of the above embodiments, the particles are nanoparticles (nanoformulations). According to some embodiment, the drug load of the loaded particles is from 20 to 70%. According to some embodiment, the drug load of the particles is from 25 to 65%, from 30 to 60%, from 35 to 55%, from 40 to 50%, or from 40 to 60%. The term “drug load” refers to the ratio between the amount of drug loaded into the particle to the amount of particles.
According to any one of the above embodiments, the particles are dry particles.
According to some embodiments, the loaded particles comprising an anti-pathogenic agent, such as antibacterial agent, encapsulated within the dendrimers of the present invention have a synergistic antipathogenic, such as a synergistic antibacterial, effect. According to some embodiments, the loaded particles comprising an antibacterial agent encapsulated within the dendrimers of the present invention have a synergistic antibacterial effect. According to some embodiments, the pharmaceutical composition is a synergistic pharmaceutical composition. As used herein, the term “synergistic” refers to a combination of a compound described herein, which, when taken together, is more effective than the additive effects of the individual therapies. A synergistic effect of a combination of therapies (e.g., a combination of therapeutic agents) permits the use of lower dosages of one or more of the therapeutic agent(s) and/or less frequent administration of the agent(s) to a subject with a disease or disorder, e.g., a proliferative disorder. The ability to utilize lower the dosage
of one or more therapeutic agent and/or to administer the therapeutic agent less frequently reduces the toxicity associated with the administration of the agent to a subject without reducing the efficacy of the therapy in the treatment of a disease or disorder. In addition, a synergistic effect can result in improved efficacy of agents in the prevention, management or treatment of a disease or disorder, e.g. a proliferative disorder. Finally, a synergistic effect of a combination of therapies may avoid or reduce adverse or unwanted side effects associated with the use of either therapeutic agent alone. Thus, the antibacterial effect of dendrimer particles loaded with antibacterial agent have an effect which is more than additive antibacterial effect of dendrimers forming said particles and of entrapped antibacterial agent.
According to any one of the above embodiments, the loaded particles formed by dendrimers and loaded with an antibacterial agent have a size of from 10 to 1000 nm. According to some embodiments, the loaded particles have a size of from 10 to 500 nm or from 10 to 100 nm. According to some embodiments, the loaded particles have a size of from 10 to 80, from 15 to 70 nm. According to some embodiments, the loaded/encapsulating nanoparticles have an average size of from 8 to 40 nm. According to some embodiments, the nanoparticles have an average size of from 10 to 35 nm. According to some embodiments, the nanoparticles have an average size of from 10 to 30 nm. According to some embodiments, the nanoparticles have an average size of from 8 to 30 nm According to some embodiments, the nanoparticles have an average size of from 10 to 25 nm.
According to some embodiments, the present invention provides a pharmaceutical composition comprising particles consisting of a hydrophobic antibacterial agent encapsulated within amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail.
According to any one of the above embodiments, the pharmaceutical composition comprising a plurality of particles comprising a hydrophobic anti-pathogenic agent encapsulated within amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail is for use in treating a pathogenic infection. According to any one of the above embodiments, the pharmaceutical composition comprising particles comprising a hydrophobic antibacterial agent encapsulated within amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail is for use in treating a bacterial infection. Any one of the abovementioned embodiments related to treating bacterial infection applies herein as well.
According to some embodiments, the present invention provides a pharmaceutical composition comprising a plurality of particles comprising dendrimers having a structure selected from Formula II, III, IV, V, VI, VII, VIII, IX, X, or XI encapsulating an actibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime for use in treating a bacterial infection. According to some embodiments, the present invention provides a pharmaceutical composition comprising a plurality of particles comprising dendrimers of Formula II encapsulating an actibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime for use in treating a bacterial infection. According to some embodiments, the particles comprising dendrimers of Formula II encapsulating ciprofloxacin. According to some embodiments, the particles comprise dendrimers of Formula II encapsulating vancomycin. According to some embodiments, the particles comprise dendrimers of Formula II encapsulating cefuroxime. According to some embodiments, the particles comprise dendrimers of Formula II encapsulating azithromycin. According to some embodiments, the particles comprise dendrimers of Formula II encapsulating doxycycline. According to some embodiments, the particles comprise dendrimers of Formula II encapsulating erythromycin. According to some embodiment, the pharmaceutical composition is for use in treating bacteria selected from Pseudomonas, Klebsiella, Staphylococcus, Borrelia and Neisseria. According to some embodiment, the pharmaceutical composition is for use in treating bacteria selected Pseudomonas aeruginosa, methicillin resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Staphylococcus aureus, Borrelia bavariensis and Neisseria meningitidis. According to some embodiment, the pharmaceutical composition is for use in treating bacteria selected Pseudomonas aeruginosa, methicillin resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, and Staphylococcus aureus. In some alternative embodiments, the particles comprise dendrimers of Formula III and the encapsulated antibacterial agent. According to some embodiments, the present invention provides a pharmaceutical composition comprising a plurality of particles comprising dendrimers of Formula IV encapsulating an actibacterial agent selected from azithromycin, ciprofloxacin, doxycycline, erythromycin, vancomycin and cefuroxime for use in treating a bacterial infection. According to some embodiments, the particles comprising dendrimers of Formula IV encapsulating ciprofloxacin. In some alternative embodiments, the particles comprise dendrimers of Formula IV and the encapsulated antibacterial agent. In some alternative embodiments, the particles comprise dendrimers of Formula V and the encapsulated antibacterial agent. In some alternative embodiments, the particles comprise
dendrimers of Formula VI and the encapsulated antibacterial agent. In some alternative embodiments, the particles comprise dendrimers of Formula VII and the encapsulated antibacterial agent. In some alternative embodiments, the particles comprise dendrimers of Formula VIII and the encapsulated antibacterial agent. In some alternative embodiments, the particles comprise dendrimers of Formula IX and the encapsulated antibacterial agent. In some alternative embodiments, the particles comprise dendrimers of Formula X and the encapsulated antibacterial agent. In some alternative embodiments, the particles comprise dendrimers of Formula XI and the encapsulated antibacterial agent. According to some embodiments, the treatment has/provides a synergistic effect. According to some embodiments, the pharmaceutical composition comprising particles comprising dendrimers of Formula II and doxycycline has a synergistic antibacterial effect, e.g. anti-MRSA effect. According to some embodiments, the pharmaceutical composition comprising particles comprising dendrimers of Formula VI and doxycycline has a synergistic antibacterial effect, e.g. anti-Borrelia effect. According to some embodiments, the pharmaceutical composition comprising particles comprising dendrimers of Formula IV and doxycycline has a synergistic antibacterial effect, e.g. anti-Neisseria effect.
According to some embodiments, the pharmaceutical composition may be administered by any known method, e.g. as described in any one of the above embodiments.
According to another aspect, the present invention provides a method of treating a pathogenic infection in a subject in need thereof comprising administering to said subject the pharmaceutical composition comprising particles comprising a hydrophobic antipathogenic agent encapsulated within amphiphilic poly(amidoamine) (PAMAM) amine- terminated dendrimers comprising a hydrophobic tail. According to another aspect, the present invention provides a method of treating a bacterial infection in a subject in need thereof comprising administering to said subject the pharmaceutical composition comprising particles comprising a hydrophobic antibacterial agent encapsulated within amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail. All terms, embodiments and definitions disclosed in any one of the above aspects apply and are encompassed herein as well.
According to some embodiments, the use comprises co-administering the pharmaceutical composition of the present invention as described in any one of the above embodiments with an additional anti-pathogenic agent. According to some embodiments, the use comprises co-administering the pharmaceutical composition particles comprising a hydrophobic antibacterial agent encapsulated within amphiphilic poly(amidoamine)
(PAMAM) amine-terminated dendrimers comprising a hydrophobic tail with an additional antibacterial agent.
According to yet another aspect, the present invention provides a method of treating a pathogenic infection in a subject in need thereof comprising administering to said subject a plurality of particles comprising a hydrophobic antipathogenic agent encapsulated within amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail as described in any one of the above embodiments and aspects, or a pharmaceutical composition thereof. All terms, embodiments and definitions disclosed in any one of the above aspects apply and are encompassed herein as well.
According to yet another aspect, the present invention provides use of particles comprising a hydrophobic antipathogenic agent encapsulated within amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail as described in any one of the above embodiments and aspects, for preparation of a medicament for treating a pathogenic infection in a subject in need thereof comprising administering to said subject a plurality of or a pharmaceutical composition thereof. All terms, embodiments and definitions disclosed in any one of the above aspects apply and are encompassed herein as well.
According to yet another aspect, the present invention provides an amine-terminated poly(amidoamine) (PAMAM) dendrimer comprising a hydrophobic tail, wherein the hydrophobic tail is an aliphatic chain comprising at least one double bond. According to any embodiment, the dendrimer is an amphiphilic dendrimer. According to some embodiments, the present invention provides an PAMAM amine-terminated dendrimer comprising a hydrophobic tail being an aliphatic chain and comprising at least one double bond. According to some embodiments, the hydrophobic tail is an alkenyl. Thus, the present invention provides an amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimer comprising a hydrophobic tail, wherein the hydrophobic tail comprises a C16- C32 alkenyl. All terms, embodiments and definitions disclosed in any one of the above aspects referring to such a composition apply and are encompassed herein as well.
According to some embodiments, the dendrimer is selected from generation 2, 3, 4 and 5 dendrimers. According to some embodiments, the dendrimer comprises 4 terminal amines. According to some embodiments, the dendrimer comprises 8 terminal amines. According to some embodiments, the dendrimer comprises 16 terminal amines. According to some embodiments, the dendrimer comprises 32 terminal amines. According to some embodiments, the dendrimer comprises 64 terminal amines. According to some
embodiments, the dendrimer comprises 4, 8, 16 or 32 terminal amines. According to some embodiments, the dendrimer is selected from generation 2, 3, 4 and 5 dendrimers and comprising 4, 8, 16 or 32 terminal amines.
According to some embodiments, the amine of the dendrimer terminus is a primary amine. According to another embodiment, the terminal amines are secondary amines. According to yet another embodiment, the terminal amines are tertiary amine. According to some embodiments, the terminal amines are positively charged at neutral and acidic pH. According to some embodiments, the terminal amines are cyclic amines. According to some embodiment, the terminal amines are amidine.
According to some embodiments, the hydrophobic tail is an alkenyl. According to some embodiments, the hydrophobic tail is an alkenyl comparing 12 to 40 carbon atoms. According to some embodiments, the hydrophobic tail is a C16-C32 alkenyl. According to some embodiments, the hydrophobic tail is a C16-C22 alkenyl. According to some embodiments, the hydrophobic tail is a C16 alkenyl. According to some embodiments, the hydrophobic tail is a C18 alkenyl. According to some embodiments, the hydrophobic tail is a C20 alkenyl. According to some embodiments, the hydrophobic tail is a C22 alkenyl. According to some embodiments, the alkenyl is a straight alkyl. According to some embodiments, the hydrophobic tail comprises a C16-C22 straight alkenyl. According to another embodiment, the alkenyl is s branched alkenyl. According to some embodiments, each chain branch of the branched alkenyl comprises 10-20 carbons. According to some embodiments, at least one branch of the branched alkenyl comprises 14 carbons. According to some embodiments, at least one branch of the branched alkenyl comprises 16 carbons. According to some embodiments, at least one branch of the branched alkenyl comprises 18 carbons.
According to some embodiments, the alkenyl comprises two double bonds, i.e., a diene. According to some embodiments, the double bonds are conjugated double bonds. According to some embodiments, the alkenyl comprises 3, 4 or 5 double bonds.
According to some embodiments, the hydrophobic tail is bound to the dendrimer via a linker. According to some embodiments, the linker may be a cyclic, aromatic or nonaromatic compound. According to some embodiments, the linker comprises a triazole or a derivative thereof. According to some embodiments, the linker is an ester, amide, or disulfide. According to some embodiments, the hydrophobic tail is bound to the core of the dendrimer.
According to some embodiments, the dendrimer has a structure of Formula I:
wherein R is selected from J , and any
combination thereof, X is a C16-C28 alkenyl. According to some embodiments, X is C16- C22 alkenyl. According to some embodiments, X is C18 alkenyl. According to some embodiments, X is C18 alkenyl. According to some embodiments, X is C20 alkenyl. According to some embodiments, X is a diene. According to some embodiments, X is a conjugated diene.
O H embodiment, R is JI, /-\ .NH2- According to yet another embodiment, X is C18 straight
According to some embodiments, (i) X is C18 straight alkenyl; (ii) R is 'x^N'x^/NH2or (iii) both (i) and (ii).
According to some embodiments, wherein the dendrimers have a structure selected from a structure of Formula V, VI, VII, and VIII, as depicted hereinabove and in Figs. 1H, II, 1J and IK, respectively.
According to one aspect, the present invention provides particles comprising a plurality of amphiphilic poly(amidoamine) (PAMAM) amine-terminated dendrimers comprising a hydrophobic tail, wherein the hydrophobic tail comprises a C16-C32 alkenyl. According to some embodiments, the hydrophobic tail is a C16-C32 alkenyl. All terms, embodiments and definitions disclosed in any one of the above aspects referring to such a composition apply and are encompassed herein as well. According to some embodiments,
the dendrimer comprises 4, 8, 16 or 32 terminal amines. According to some embodiments, the dendrimer is selected from generation 2, 3, 4 and 5 dendrimers.
According to some embodiments, the present invention provides particles comprising a plurality of particles comprising and formed by dendrimers having a structure of Formula I:
wherein R is selected from , and any
combination thereof, X is a C16-C28 alkenyl. According to some embodiments, X is C16- C22 alkenyl. According to some embodiments, X is C18 alkenyl. According to some embodiments, X is C18 alkenyl. According to some embodiments, X is C20 alkenyl. According to some embodiments, X is a diene. According to some embodiments, X is a conjugated diene.
According to some embodiments, the present invention provides particles comprising and formed by dendrimers having a structure selected from Formula V, VI, VII, and VIII.
According to some embodiment, the particles further comprise a biologically active agent. According to some embodiment, the particles encapsulate comprise a biologically active agent. In some embodiments, the biologically active agent is a nucleic acid. The term “nucleic acid” refers to a single- stranded or double- stranded sequence (polymer) of deoxyribonucleotides or ribonucleotides. In addition, the polynucleotide includes analogues of natural polynucleotides, unless specifically mentioned. According to an embodiment, the nucleic acid may be” selected from the group consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), peptide nucleic acid (PNA), locked nucleic acid (LN A), and
analogues thereof, but is not limited thereto. The term encompasses DNA, RNA, single stranded or double stranded and chemical modifications thereof. According to some embodiments, the nucleic acid is DNA. According to some embodiments, the nucleic acid is RNA.
According to some embodiments, the biologically active agent is an active agent. The term "active agent" and “active moiety” are used herein interchangeable and refer to an agent that has biological activity, pharmacologic effects and/or therapeutic utility. According to some embodiments, the active agent is a small molecule. According to some embodiments, the active agent is an anti-pathogenic agent. The anti-pathogenic agent is as described and defined in any one of the above aspects and embodiments. According to some embodiments, the anti-pathogenic agent is an antibacterial agent. According to some embodiments, the anti-pathogenic agent is a hydrophobic antibacterial agent. According to some embodiments, the hydrophobic antibacterial agent is selected from rifampin, vancomycin, erythromycin, clarithromycin, azithromycin, tetracycline, doxycycline, chloramphenicol, clindamycin, linezolid, ciprofloxacin, levofloxacin, norfloxacin, moxifloxacin, gentamicin, amikacin, kanamycin, neomycin, streptomycin, polymyxin b, daptomycin, fosfomycin, imipenem, meropenem, nafcillin, oxacillin, penicillin g, piperacillin, ticarcillin, trimethoprim, sulfamethoxazole, rifabutin, colistin, teicoplanin, telithromycin, tigecycline, mupirocin, bacitracin, nitrofurantoin, and clavulanate.
According to some embodiments, the present invention provides a composition comprising a plurality of amphiphilic amine-terminated PAMAM dendrimers of the present invention comprising a hydrophobic tail, wherein the hydrophobic tail comprises a C16-C32 alkenyl or a plurality of particles comprising same, and a carrier. According to some embodiments, the composition is a pharmaceutical composition comprising a pharmaceutically acceptable carrier. According to some embodiment, the pharmaceutical composition comprising the dendrimers, the particles and/or the particles comprising an anti- pathogenic agent are for use in treating pathogenic infection. According to some embodiments, the pathogenic infection is bacterial infection. According to some embodiments, the particles comprising the dendrimer as described hereinabove and an antibacterial active agent provide a synergistic antibacterial effect.
According to another aspect, the present invention provides an amine-terminated polyamidoamine bola- amphiphilic dendrimer, wherein the terminal amine is a tertiary amine. According to some embodiments, the bola-amphiphilic amine-terminated PAMAM dendrimer is of 1st, 2nd, 3rd, 4th, 5th or 6th generation of PAMAM. According to some
embodiments, the amine-terminated PAMAM bola- amphiphilic dendrimer has a structure of Z-Y-Z, wherein:
Z has the structure of Formula I:
wherein R is selected from . N^NH , and any
combination thereof, and X is a moiety selected from C8-C16 alkyl, Cl l alkyl, C8-C16 alkenyl and Cl l alkenyl and Y is a linker. According to some embodiments, X is C8-C14, C9-C13, CIO, Cl l, or C12 alkyl. According to some embodiments, X is C8-C14, C9-C13, CIO, Cl 1, or C 12 alkenyl. According to some embodiments, the linker has a structure
According to some embodiments, the linker is a disulfide linker. According to some embodiments, the linker is a moiety comprising a disulfide. According to some embodiments, the linker is a disulfide-comprising linker. According to some embodiments, the amine-terminated polyamidoamine bola-amphiphilic dendrimer has a structure of formula XIII as described above and provided in Fig. IM.
According to some embodiments, the present invention provides a composition comprising the bola-amphiphilic PAMAM amine-terminated dendrimer as described in the above embodiments of the aspect and a carrier. According to some embodiments, the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier. According to some embodiments, the composition is for use in treating a pathogenic infection, such as a bacterial infection.
The terms “a,” “an,” and “the” are used herein interchangeably and mean one or more.
The term “and/or” is used to indicate one or both stated cases may occur, for example A and/or B includes, (A and B) and (A or B).
The term “or,” as used herein, denotes alternatives that may, where appropriate, be combined; that is, the term “or” includes each listed alternative separately as well as their combination if the combination is not mutually exclusive.
The terms “comprising”, "comprise(s)", "include(s)", "having", "has" and "contain(s)," are used herein interchangeably and have the meaning of “consisting at least in part of’. When interpreting each statement in this specification that includes the term “comprising”, features other than that or those prefaced by the term may also be present. Related terms such as “comprise” and “comprises” are to be interpreted in the same manner. The terms “have”, “has”, having” and “comprising” may also encompass the meaning of “consisting of’ and “consisting essentially of’, and may be substituted by these terms. The term “consisting of’ excludes any component, step or procedure not specifically delineated or listed. The term “consisting essentially of’ means that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods.
As used herein, the term “about”, when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of +/- 10%, or +/-5%, +/-1%, or even +/-0.1% from the specified value.
Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.
EXAMPLES
Materials and Methods
General/materials
The ester-terminating dendrimer 1 was synthesized according to the well-established protocol published in Yu et al., Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8478-84. Synthesis of dendrimer la and lb was carried out by amidation of the ester-terminating dendrimer precursor 1 using ethylenediamine and A,A-dimethylethylenediamine respectively according to previously developed protocol (Chen et al., Gene Silencing. Small 2016;12:3667-76; Wu et al., 2005 Jan 21 ;(3):313-5). Whereas synthesis of dendrimer 1c was obtained by conjugation of la with the protected arginine followed by subsequent deprotection. The acid-terminated dendrimer Id was synthesized via hydrolysis of 1 using
LiOH. Chemicals were purchased from Sigma Aldrich or Alfa Aesar. Methyl acrylate, ethylenediamine, N, A-Dimethylethylenediamine, dichloromethane and methanol were dried according to the described methods and distilled before use. The other chemicals were used without further purification. For inner/outer membrane assays N-phenyl-1 -naphthylamine (NPN) Arcos Organics (98%),,3'-Di-n-propylthiadicarbocyanine iodide [DiSC3(5)] Alfa Aesar (96%) were used. Dialysis tubing was purchased from Sigma Aldrich (St. Quentin Fallavier, France) and Yuanye Bio-Technology Co., Ltd. (Shanghai, China). Analytical thin layer chromatography (TLC) was performed using silica gel 60 F254 plates 0.2 mm thick with UV light (254 and 364 nm) as revelator. Chromatography was prepared on silica gel (Merck 200-300 mesh).
1 H and 13C NMR spectra were recorded on Bruker Avance III 400 (400 MHz, 1 H; 100 MHz, 13C) and Varian Mercury- VX600 (600 MHz, XH; 150 MHz, 13C). Chemical shifts (<5) are expressed in parts per million (ppm). The HRMS analysis was carried out with a SYNAPT G2 HDMS (Waters) mass spectrometer equipped with a pneumatically assisted atmospheric pressure ionization (API) source. The sample was ionized in positive electrospray mode under the following conditions: electrospray voltage: 2.8 kV; orifice voltage: 20 V; Nebulization gas flow (nitrogen): 100 L / h. The high resolution mass spectrum (MS) was obtained with a flight time analyzer (TOF). The exact mass measurement was done in triplicate with an external calibration. The sample is dissolved in 300 pL of methanol and then diluted 1/10 in a 1.0% solution of methanol formic acid. The solution of the extract is introduced into the infusion ionization source at a flow rate of lOpL/min.
Synthesis of the amphiphilic 3rd generation dendrimers la-d la: To a solution of 1 (98 mg, 0.057 mmol) in methanol (2.0 mL) was slowly added ethylenediamine (2.0 mL, 30 mmol) under ice bath. Then the reaction mixture was stirred for 3 days at 30 °C until IR showed the complete disappearance of the ester functions in 1. The reaction solution was evaporated, and the obtained residue was purified by dialysis (change dialysis water one hour per time for 6 times) and lyophilization. Repeating the operation cycles of dialysis and lyophilization for 3 times, the product was lyophilized to yield the corresponding la as a white solid (96 mg, yield: 86%)
’ H NMR (400 MHz, CDC13/CD3OD=3/1): 8 7.54 (s, 1H, CH), 4.17 (t, 2H, J = 7.4 Hz, CH2), 3.62 (s, 2H, CH2), 2.98-3.11 (m, 28H, CH2), 2.51-2.64 (m, 44H, CH2), 2.29-2.42 (m, 12H, CH2), 2.34-2.42 (m, 28H, CH2), 1.64-1.77 (m, 2H, CH2), 0.98-1.21 (m, 30H, CH2), 0.70 (t, 3H, J = 6.8 Hz, CH3); 13C NMR (150 MHz, CD3OD): 8 174.0, 173.6, 173.5,143.6, 124.0,
53.4, 52.3, 50.2, 49.9, 49.3, 41.7, 41.5, 40.8, 37.4, 33.6, 31.9, 30.2, 29.6, 29.4, 29.3, 28.9,
26.4, 22.5, 13.3; IR (cm’1): u 1644.6; HRMS: calculated for C9iHi86N32Oi44+ [M+4H]4+ 488.1208, found 488.1294. lb: To a solution of 1 (100 mg, 0.058 mmol) in methanol (5.0 mL) was added N,N- dimethylethylenediamine (2.5 mL, 28 mmol). The reaction mixture was stirred for 5 days at 50 °C until the IR and NMR analysis showed the complete disappearance of the ester functions in 1. The reaction solution was evaporated, and the obtained residue was purified by precipitation with CH3OH/ECO for three times and followed by dialysis (change dialysis water one hour per time for 6 times) and lyophilization. Repeating the operation cycles of dialysis and lyophilization for 3 times, the product was lyophilized to yield the corresponding lb (108 mg, 86%) as a pale viscous oil.
1 H NMR (400 MHz, CDC13): 6 7.90 (t, 2H, J = 5.3 Hz, NH), 7.73 (t, 4H, J = 5.2 Hz, NH), 7.57 (s, 1H, CH), 7.52 (t, 8H, J = 5.2 Hz, NH), 4.28 (t, 2H, J = 7.4 Hz, CH2), 3.81 (s, 2H, CH2), 3.24-3.32 (m, 28H, CH2), 2.72-2.75 (m, 28H, CH2), 2.51-2.62 (m, 12H, CH2), 2.40- 2.43 (m, 28H, CH2), 2.34-2.42 (m, 44H, CH2), 2.30 (br, 48H, CH2), 2.02 (br, 2H, CH2), 1.23 (br, 30H, CH2), 0.84 (t, 3H, J = 6.8 Hz, CH3); 13C NMR (100 MHz, CDCI3): 6 172.7, 172.6, 172.4, 143.4, 122.9, 58.3, 52.6, 50.2, 50.1, 45.3, 45.3, 37.0, 34.5, 31.9, 29.7, 29.7, 29.5, 29.4, 26.6, 22.2, 14.2; IR (cm’1): u 1648; HRMS: calculated for Cio7H2i4N32Oi4 3+ [M+3H]3+ at 724.9079, found 724.9038.
1c: To a solution of Fmoc-Arg(pbf)-OH (726 mg, 1.12 mmol), HOBt (171 mg, 1.12 mmol), HBTU (424 mg, 1.12 mmol) and DIPEA (389 pL, 2.24 mmol) in 10.0 mL DMF stirring at 25 °C under argon, was added a solution of la (68 mg, 0.035 mmol) in 5.0 mL DMF. The resulting solution was stirred at 25 °C under argon for 2 days. Then DMF was removed under reduced pressure, and the residue was purified by precipitation with CH3OH/ECO (1.0 mL/20 mL) at 4.0 °C for 12 h (three times). The residual precipitate was collected, dried by rotavap and then dissolved in 8.0 mL 30% piperidine in DMF (v/v). The mixture was stirred at 25 °C under argon for 2.0 h, and DMF was then removed under reduced pressure. The residue was purified by precipitation with CH3OH/ECO (1.0 mL/12.0 mL) at 4.0 °C for 12 h (three times). A solution of 95% TFA, 2.5% triisopropylsilane (TIS) and 2.5% H2O (v/v/v, 5.0 mL) was added to the residual precipitate and stirred at 25 °C under argon for 1 h. The crude product was dissolved in water (2.0 mL) and filtered, then purified by dialysis (change dialysis water one hour per time for 6 times) and lyophilization. Repeating the operation cycles of dialysis and lyophilization for 3 times, the product was lyophilized to yield the corresponding 1c as a white solid (125 mg, yield: 86%).
1c: ’ H NMR (600 MHz, D2O): 8 7.87 (s, 1H, CH), 4.26 (t, 2H, J = 6.3 Hz, CH2), 3.76-3.81 (m, 10H, CH2), 3.11-3.28 (m, 28H, CH2), 3.05 (t, 16H, J = 6.9 Hz, CH2), 2.91- 2.96 (m, 28H, CH2), 2.66-2.80 (m, 28H, CH2), 2.37-2.43 (m, 28H, CH2), 1.71-1.79 (m, 18H, CH2), 1.46-1.48 (m, 16H, CH2), 1.00-1.05 (m, 30H, CH2), 0.65 (t, 3H, J = 6.6 Hz, CH3); 13C NMR (150 MHz, D2O): 8 173.8, 173.4, 170.2, 157.5, 156.9, 117.4, 115.5, 53.1, 53.0, 51.8, 49.4, 40.4, 39.2, 38.8, 35.6, 32.3, 29.1, 28.2, 23.7; IR (cm-1): v 1630.3; HRMS: calculated for Ci39H283N64O22 5+ [M + 5]5+ 640.4598, found 640.4614.
Id: To a solution of ester dendrimer (300 mg, 0.17 mmol) in MeOH (5.0 mL) was added dropwise LiOH H2O (117 mg, 2.8 mmol) in H2O (5.0 mL) at 0 °C. The reaction solution was stirred at 0 °C for 10 min and then moved to 25 °C for 24 h. When the reaction was completed indicated by NMR monitoring, MeOH was evaporated and the pH of the aqueous phase was adjusted to 4.0 using 1.0 M HC1 solution, then purified by dialysis (change dialysis water one hour per time for 6 times) and lyophilization. Repeating the operation cycles of dialysis and lyophilization for 3 times, the product was lyophilized to yield the corresponding Id as a white solid (231 mg, yield: 83%).
’ H NMR (400 MHz, CD3OD): 8 8.07 (s, 1H, CH), 4.41 (t, J = 7.1 Hz, 2H, CH2), 4.13 (s, 2H, CH2), 3.70-3.60 (m, 12H, CH2), 3.49-3.24 (m, 36H, CH2), 3.01 (t, J = 6.8 Hz, 4H, CH2), 2.81 (t, J = 6.6 Hz, 8H, CH2), 2.68-2.59 (m, 20H, CH2), 1.95-1.87 (s, 2H, CH2), 1.36-1.24 (m, 30H, CH2), 0.90 (t, J = 6.7 Hz, 3H, CH3); 13C NMR (101 MHz, CD3OD): 3 177.2, 173.9,
173.3. 140.9. 126.8, 53.8, 53.0, 51.8, 51.4, 50.6, 50.1, 47.6, 35.6, 33.1, 32.5, 31.5, 31.3, 31.1,
30.8, 30.8, 30.7, 30.6, 30.5, 30.2, 27.6, 23.7, 14.5; IR (cm-1): v 1710.2; HRMS: calculated for C75Hi37Ni6O22 3+ [M+3H]3+ 538.0026, found 538.0029.
Critical micelle concentration (CMC)
CMC was determined using pyrene as a fluorescence probe. Dendrimers stock solution was prepared in water and aliquots of the stock solutions were diluted by water to get desired concentration (1.0 pM to 1000 pM) in 1 mL solution. 1.0 pL of pyrene was added from its 1.0 mM stock solution prepared in ethanol and solutions were vortexed for 5 min and kept at room temperature for 24 h. Florescence emission was recorded at 373 nm and 384 nm using an excitation wavelength of 334 nm on CARY Eclipse fluorescence spectrophotometer at room temperature. Excitation and emission bandwidths were 5 nm. The fluorescence intensity ratio of I373/I383 was analyzed and a sigmoidal best fit analysis was applied to fluorescence intensity ratio data. The CMC was determined by plotting normalised fluorescence intensity ratio of pyrene I1/I3 against Log concentration of dendrimers.
Transmission electron microscopy (TEM)
TEM was performed using JEOL 3010 transmission electron microscope (Tokyo, Japan) to characterize the size and morphology of the NPs at an accelerating voltage of 300 kV. The dendrimers were dispersed in milliQ water at a concentration of 1.0 mg/mL, and sonicated for 30 sec, then the solutions were diluted 100-fold and followed by depositing an aliquot (4.0 pL) onto a carbon-coated copper grid and dried at 37 °C. The grid was then stained with 3.0 pL uranyl acetate (2.0% in aqueous solution) for 4 sec, and the excess uranyl acetate was removed by filter paper before measurements. For each sample, at least 300 particles in different TEM images were randomly selected and measured by using ImageJ software to calculate the size and the size distribution of the nanoparticles.
Zeta potential measurement
Solutions of dendrimers were prepared in H2O with pH adjusted to 7.4 using 0.10 M NaOH/0.01 M HC1. After incubated at room temperature for 30 min, zeta potential measurement was performed using Zetasizer Nano-ZS (Malvern, Ltd. Malvern, U. K.) with a He-Ne ion laser of 633 nm. The experiments were done in triplicates.
Dru /dendrimer encapsulation
The film dispersion method was used to encapsulate the antibiotics azithromycin (AZM) and Ciprofloxacin (CIP) in the self-assembling dendrimer nanomicelles. Stock solution hydrophobic AZM and CIP as well as dendrimers were prepared in methanol. Antibiotic drugs solutions were mixed with the solution of la, resulting in different mass ratio of antibiotic s/dendrimer (from 0.2:1 to 1:1). The solvent of methanol was evaporated by vacuum rotary evaporation to form a dry film. The dry film was hydrated with water or PBS buffer for 5 min under constant stirring. Non-encapsulated antibiotic drugs were separated by filtration through a 0.45-pm polycarbonate membrane (Millipore Co.) and products were subsequently lyophilized. The amount of encapsulated antibiotic drugs in the micelles was measured using HPLC. The % encapsulation efficiency and % drug loading were calculated as below:
% drug loading: Wt/Ws x 100
% encapsulation efficiency: Wt/W0 x 100
Wt represents the amount of antibiotic drug that loaded into nanoparticles; Wo represents the initial amount of antibiotic drug fed; Ws represents the amount of nanoparticles after lyophilization.
Cells
Human embryonic kidney 293 cells (HEK 293 cells) and mouse fibroblast cells (L929 cells) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Invitrogen) containing 10% fetal bovine serum (FBS) (Biosera). Cells were maintained at 37°C with 5% CO2 in a humidified chamber.
Bacterial cells
Pseudomonas aeruginosa PAO1, Staphylococcus aureus RN4220, JLA513 and Methicillin-resistant staphylococcus aureus (MRSA) 1206 were used. The strains were grown in lysogeny broth (LB) or LB agar plates at 37°C. Bacteria were stored at -80 °C in 25% glycerol and at 4.0 °C on LB agar plate. PrestoBlue assay
L929 and HEK 293 cells were seeded at 1.0 x 104 cells/well and 4.0 x 103 cells/well in 96-well plates and allowed to grow overnight. Cells were then treated with various concentration (0.10 - 200 pM) of the amphiphilic dendrimers la-d for 48 h. Then 10 pL PrestoBlue reagent was added to each well containing 100 pL of blank, control, or treated cells in culture and incubated for another 3 h at 37 °C. The changes in cell viability were detected using fluorescence spectroscopy (excitation 570 nm; emission 610 nm). The cell viability was expressed as a percentage relative to the cells untreated with dendrimers. All samples were run in triplicate. Hemolysis assay
Red blood cells (RBCs) were isolated from the freshly collected whole blood of Swiss nude mice (with 1.0% heparin sodium solution). Blood was centrifuged at 7500 rpm for 10 min. several wash of PBS buffer given to RBCs until no color was seen in the supernatant. 2.0% RBCs concentration was achieved by diluting them in PBS (e.g. 20 pL of RBC suspension added to 0.98 mL PBS). 0.50 mL of 2.0% RBC solution was added into 1.5 mL Eppendorf tubes, and then 0.50 mL of dendrimer at different concentrations (2.0, 10.0, 20.0, 100, 200 and 500 pM) were added to make the final concentration 1.0, 5.0, 10.0, 50, 100 and 250 pM. 0.50 mL RBC suspension incubated with 0.50 mL PBS or 0.50 mL 1.0% TritonX-100 solution was used as the negative control and positive control, respectively. The samples were mixed gently, left at 37 °C for Ih, then centrifuged at 7500 rpm for 10 min. Then the supernatant was analyzed for the absorbance of hemoglobin at 540 nm on fluorescence spectrometer. The percentage of hemolysis was calculated as follows: Hemolysis% = [(sample absorbance - negative control) / (positive control - negative control)] xl00%.
Minimum inhibitory concentration (MIC)
Minimal-inhibition concentration (MIC) assay was performed as described in Hayouka et al (J Am Chem Soc. 2013,135(32):11748-51. doi: 10.1021/ja406231b). Briefly, stock solutions of the tested compounds were diluted in LB broth and then diluted in 96-well plates (Coming 3650) with a 2-fold dilution, from 200ug/ml to3.1pg/ml. Bacteria were grown overnight (37°C, 200rpm), then diluted 1 : 100 and grown to OD600 of 0.1, subsequently lOOpL were added into the 96-well plate. Bacterial growth was determined after incubation of 24 h at 37°C by measurement of the optical density (OD600nm), using a Tecan infinite Pro Plate reader. MIC value defined as the lowest concentration at which there is complete inhibition of bacterial growth (no increase in OD over the course of the experiment). Each experiment was carried out at least three times, with three replicates per strain/concentration combination in each experiment.
Antibacterial activity assay against biofilms
Biofilm Inhibition assay
One colony of S. aureus JLA513 was inoculated from agar plate into 5.0 mL TSB media (50 mL tube) and grown overnight. The overnight suspension diluted 1:100 in fresh TSB supplemented with 1.0 % D-glucose (TSBG) and grown until ODs95 = 0.1. The bacterial suspension was then diluted 1 : 100 in TSBG and 100 pL were transferred into 96-well plate, which contained a serial concentrations of the dendrimer la in TSBG. The plate was then incubated for 48 hours at 37 °C. Then the supernatant liquid was discarded and the wells were washed with DDW 3 times. Dendrimer 2 was used as negative control. Biofilm quantification by MTT
For quantification of biofilm viability, the tetrazolium dye 3-[4,5-dimethyl-2- thiazolyl]-2, 5-diphenyl-2H-tetrazolium-bromide (MTT) was used as previously described with modifications. Briefly, after the 96-well plate washed from unattached cells and dried, 50 pL of MTT dissolved in PBS (0.50 pg/mL, pH 7.4) added to each well and incubated at 37 °C for 2 hours. Subsequently, 100 pL of DMSO were added to each well and incubated for 15 minutes. Then, the OD595 was measured using Tecan plate reader. The results were normalized to the control strain that was grown in the absence of antimicrobial agents. Crystal violet assay for biomass quantification:
The wells were treated with 125pL of 0.1% crystal violet and incubated for 15 min at 37 °C (G. A. O'Toole and R. Kolter, Mol Microbiol, 1998, 30, 295). Excess crystal violet was washed off thoroughly with milli-Q water three times. 125pL of 30% acetic acid was
added to each well and the solution was transferred to a new 96-well plate, and absorbance was measured at 550 nm (Tecan plate reader) using 30% acetic acid in water as blank. The results were expressed as a percentage of biomass in the control biofilm, which was grown without any treatment.
Live/dead staining and fluorescence microscopy analysis
E. coli rp/MRSA culture was grown overnight in LB, and was then centrifuged and washed in PBS buffer for three times. The suspension was diluted to OD600 of 0.1. Incubation of 1 mL bacterial cells suspension was performed with shaking (200 RPM) with 25 pg/mL of tested compound (al) for 30 minutes (37°C). Incubation of the bacteria with PBS was used as control. After incubation, the bacterial cells were stained using LIVE/DEAD BacLight Bacterial Viability Kit (ThermoFisher). Each sample was incubated with 2.5 pL propidium iodide (red) and 2.5 pL SYTO9 (green) for 15 minutes in the dark. Afterwards fluorescent images were taken using EVOS M5000 imaging system (ThermoFischer). Images were analyzed using the software imageJ.
Outer membrane permeabilization assay
The outer membrane permeability was determined using the fluorescent probe biphenyl- 1 -naphthylamine (NPN). E. coli cells were grown overnight in LB media, then diluted 100-fold in LB and grown at 37°c to OD600 of 0.5. The cells were then washed with 5mM sodium HEPES buffer (pH 7.2), and resuspended in the same buffer to OD600 of 0.2. Subsequently, lOOuL of the suspended bacteria was added into 96-well plate (Nunc, Thermo Scientific, 167008) with 50 pl of NPN solution (lOuM). Fluorescence intensities were measured using Synergy Hl Biotek microplate reader (excitation: 350, emission: 420) for 5 minutes, then 50 pl of the tested compounds were added into each well and the fluorescence intenseties were measured for additionally 40 minutes. 8A molecule was used as negative control. The displayed results are representative of 3 independent experiments with 3 replicates for each treatment.
Inner membrane permeabilization assay
Depolarization of the inner membrane was assessed using the lipophilic potentiometric dye 3,3'-Dipropylthiadicarbocyanine Iodide [DiSC3(5)]. E. coli and MRSA bacterial cells were grown overnight in LB media (37°C, 200rpm), then diluted 1 :100 in LB and grown to OD600 of 0.5. Bacteria were then washed with 5mM HEPES, 20 mM glucose and 0.1M KC1, and resuspended in the same buffer to approximately 106 CFU/ml. The bacterial cells were then incubated with 0.4pM DiSC3(5) for 1 hr in 96-well plates (Nunc, Thermo Scientific, 167008), until a stable reduction of fluorescence was achieved. The tested
compounds at the indicated concentrations, were then added to the bacterial sample and the changes in the fluorescence intensities were monitored using Synergy Hl Biotek microplate reader (excitation: 647, emission: 677). Triton-X 0.5% was used as positive control, 8A dendrimer (200 pg/ml final concentration) was used as a negative control. Results displayed are representative of 3 independent experiments with three replicates for each treatment. Scanning electron microscopy
E. coli rp and MRS A cultures were each grown overnight in LB, then centrifuged and washed in PBS buffer for three times. The suspension was diluted to OD600 of 0.1, to get -107 CFU/mL. Incubation of 1 mL bacterial suspension was incubated with shaking (200 RPM) with 6.3 or 50 pg/mL with the tested compound in PBS buffer at 37°C for 30 minutes. Incubation of the bacteria in PBS only, and dendrimer la in PBS were used as control. After incubation, the bacteria were centrifuged (4000 RPM, 5 minutes) and resuspended with 100 pL 4% glutaraldehyde in PBS was added to the samples for 1 hr at room temperature. The treated bacterial cells were dropped on a glass disk with poly-lysin, 30 pL at each side of the disk. Dehydration of the samples with the treated or non-treated bacteria was done in increasing concentrations of ethanol (25, 50, 75, 95, 100% ethanol in deionized water), 5 minutes twice for each concentration. Drying was performed with K850 critical point dryer (CPD BAL-TEC CPD-030). The samples were dried with ethanol and for 3 min in -10 °C and 20 min in 34 °C. The ethanol was replaced by liquid CO2 at ~40°C for 20 min. Then, iridium coating was performed with Q150T ES Spatter Coater. The microphotographs were recorded using imaging Jeol JSM 7800 SEM.
Example 1. Dendrimers
Synthesis
The amphiphilic dendrimers la-d were first synthesized starting with the common ester-terminating dendrimer 1 (Fig. 1A). Using our reported protocols, we prepared la and lb via the amidation of 1 with ethylenediamine and A,A-dimethylethylenediamine, respectively. Compound 1c was further obtained by conjugating la with the protected arginine followed by subsequent deprotection, whereas the carboxylic acid-terminated dendrimer Id was synthesized via hydrolysis of 1 using LiOH. The structural integrity and purity of all the synthesized dendrimers were confirmed using 1 H- and 13C-NMR as well as high-resolution mass spectroscopy. The resulted structures are presented in Fig. 1B-1D. Additionally, dendrimers of the first and second generation were prepared as shown in Figs. IE, Fig. IF (DDC18-4TA) and Fig. 1G (DD4TA). Further, dendrimers with a long C18
alkenyl hydrophobic tail (Figs. 1H-1K, denoted as DD01e8A, DD01e8TA, DDLin8A and DDLin8TA, respectively) were prepared.
Further, bola-amphiphilic PAMAM amine-terminated dendrimers (2nd and 3rd generation PAMAM dendrimers) were prepared and shown in Figs. IL, IM and IN (denoted as JCB4A, MBola-8T and JCB8A, respectively)
Water solubility
All the dendrimers la-d were soluble in water, with concentrations up to 20 mM. By virtue of the amphiphilic character and the dendritic structure, all the dendrimers selfassembled into small and spherical supramolecular nanomicelles with size ranging from 10 to 20 nm as demonstrated by transmission electronic microscopy (TEM) imaging (See Fig. 2). The nanomicelles formed by the dendrimers la-d had zeta potentials of +35 mV, +23 mV, +40 mV and -13 mV, respectively, in line with the distinct chemical entities at their terminals. The absolute values of the zeta potentials were all over 10 mV, highlighting the colloidal stability of these nanomicelles.
The self-assembly of the amphiphilic dendrimers la-ld were further studied by determining their critical micelle concentrations (CMC) using a fluorescence spectroscopic method based on pyrene. Id showed the lowest CMC value of 4.0 pM, whereas la and lb had similar CMC values of 15 and 17 pM, and 1c had the highest CMC value of 35 pM (Tables 1 and 2). The differing CMC values for la-ld can be likely ascribed to their structural feature: 1c has the largest hydrophilic entity and the greatest steric hindrance of the terminals among all the four dendrimers, hence the least packing and assembling ability therefore the highest CMC. On the other hand, dendrimer Id has the smallest hydrophilic entity, hence the highest packing ability and lowest CMC value.
Table 1: Self-assembly and toxicity of the dendrimers la-d.
aCMC: critical micelle concentration; bCytotoxicity IC50: concentration of a dendrimer required for 50% inhibition of cell growth; CL929: fibroblast cells; dHEK293: human kidney cell; eHemolysis IC50: concentration to lysis 50 % of red blood cells.
Toxicity
To evaluate the safety of these dendrimers, their cytotoxicity on fibroblast (L929) and kidney (HEK293) cell lines was determined using the PrestoBlue assay. No notable adverse effect was observed for dendrimers la, lb and Id at concentrations up to 200 pM, whereas dendrimer 1c showed considerably toxicity towards both cell types (Table 1 and Fig. 3). The hemolytic activity of the dendrimers on mouse red blood cell (RBC) was also examined. Similarly to the trend observed for cytotoxicity, 1c had the highest hemolytic activity, with IC50 value of 50 pM for 1c and 100 pM for la, lb, whereas Id did not show any notable hemolysis even at 250 pM (Table 1 and Fig. 4E). The observed toxicity of 1c may be ascribed to the arginine terminals, which interact and interfere strongly with the eukaryotic cell membrane via both electrostatic interaction and bivalent hydrogen bonds. Therefore, except dendrimer 1c, all the other dendrimers showed low cytotoxicity and good biocompatibility.
The cytotoxicity of all the synthesized dendrimers using label free high contrast microscopy was further evaluated. Among them, the dendrimers lb, Id, DDC18- 4TA, DDlin- 8TA, and DDole- 8TA showed no cytotoxicity to HEK293 cells up to 66 pM.
Example 2. Antibacterial activity of dendrimers
The antibacterial activity of dendrimers la-ld against the Gram-negative bacteria Escherichia coli (E. coli) and Pseudomonas aeruginosa (P. aeruginosa) as well as the Grampositive bacteria Staphylococcus aureus (S. aureus) and methicillin -resistant Staphylococcus aureus (MRSA) was then evaluated. The minimum inhibitory concentrations (MIC) of these dendrimers against the tested bacteria were obtained using microdilution broth assay (Table 2). Remarkably, the amine-terminated dendrimer la exhibited strong antibacterial activity against both Gram-negative and Gram-positive as well as drug-resistant MRSA, with MIC values of 3.1 pM. Interestingly, the tertiary amine- terminated dendrimer lb showed activity similar to that of la towards E. coli, but was not effective against all other tested bacteria, implying possible narrow -spectrum antibacterial activity specific to certain bacteria. Surprisingly, the arginine-terminated dendrimer 1c was not active against all the tested bacteria although 1c is the most toxic toward eukaryotic cells. Also, the carboxylic acid-terminated dendrimer Id was devoid of notable activity, in contrast to the amphiphilic dendrimers previously reported.
Table. 2 Antibacterial activity of the dendrimers la-d.
It is to note that the distinct antibacterial activities of the dendrimers could be ascribed to their different terminal groups, which interact variably with bacteria. The inactive Id can be readily explained by its negatively charged carboxylate terminals, which generate repulsion when approaching the negatively charged bacteria membrane, hence preventing antibacterial activity. Although the dendrimers la, lb and 1c all have positively charged terminals at neutral pH under physiological conditions, the primary amine groups in la, by virtue of the small size and highly positive charge, could interact strongly with the bacterial membrane surface; whereas the arginine residues in 1c with the delocalized positive charges on the guanidine scaffolds, could not offer sufficient interaction with bacterial cell membrane, hence devoid of antibacterial activity. Meanwhile, the tertiary amine terminal, which is larger than the primary amine yet smaller than the guanidine moiety, has lower charge density than the primary amine but higher than the guanidine group, therefore the dendrimer lb bearing tertiary amine terminals generated rather susceptible and variable activity toward different bacteria. This finding might be interesting to be further exploited for developing selective and narrow- spectrum antibacterial agents.
The ability of the most potent dendrimer la to disrupt the bacterial membrane using SYTO9 and propidium iodide (PI) dyes for staining the live and dead cells, respectively was next assessed. SYTO9 is a universal dye that crosses intact membranes and stains nucleic acids of all cells, whereas PI can only cross compromised bacterial membranes, and emit green fluorescence when binding to nucleic acids. Therefore, SYTO9 stains live cells, while PI staining is an indicator of membrane integrity and cell death. Figs. 4A and Fig. 4B show that the live bacteria of both Gram-negative E. coli and Gram-positive S. aureus were damaged after treatment with dendrimer la, supporting the potent antibacterial activity of la. These findings also imply that la may kill bacterial cells by a mechanism that most likely involves membrane damage.
To visualize the bacterial membrane integrity and morphology upon treatment with la, scanning electron microscopy (SEM) studies were performed. E. coli and S. aureus cells
upon treatment with la at MIC (6 pg/mL) clearly showed irregularities in cell surface with appearance of blebbing and surface deformations indicating loss of membrane integrity (Figs. 4C, 4D). At a higher la concentration (50 pg/mL) drastic cell lysis was observed with triggered release of ions and cellular materials. Untreated cells were used as a control and showed normal and smooth surface under the SEM.
To verify whether the antibacterial mechanism of la was related to the interaction with bacterial membrane, the permeability and depolarization of the bacterial outer membrane (OM) and inner membrane (IM) were evaluated. Following treatment with la, significant outer membrane permeation was observed in E. coli by monitoring the change in the fluorescent properties of the N-phenyl-1 -naphthylamine (NPN) dye (Fig. 5A), a probe which displays increased fluorescence upon binding to hydrophobic membrane regions. Furthermore, rapid inner membrane depolarization was observed in both E. coli and MRSA treated with la, as indicated by the rapid increase of the fluorescence intensity of the 3,3'- dipropylthiadicarbocyanine iodide (diSC3(5)) lipophilic potentiometric probe (Figs. 5 B and C, respectively). Both outer membrane permeation and inner membrane depolarization, match the bacterial cell death observed using the live/dead cell analysis (Fig. 4), suggesting that the bacterial death was associated with permeation and depolarization of both the outer and the inner membranes.
Encouraged by the excellent antibacterial activity alongside the safety profile of la, its activity against the biofilm formed by MRSA was further evaluated. Remarkably, la retained its antibacterial activity against MRSA biofilm with the MIC value remaining at 3.1 pM (Fig. 4F), confirming the promising potential of la as the effective antimicrobial candidate also against drug-resistant bacteria and bacteria within the biofilm matrix
Further, the antibacterial activity of several dendrimers against Borrelia bavariensis and Neisseria meningitidis was tested and the results are presented in Table 3. The MIC of all compounds for against Borrelia bavariensis (bacteriostatic effect) was about 50 pM. Borrelia spirochaete typically enters the skin after an infected tick bite and then spreads to various body parts such as the heart, joints, and central nervous system. High doses of antibiotics are needed and currently used to treat acute and chronic infection, and with no human vaccine available, Eyme arthritis (caused by this bacterim) and neuroborreliosis pose significant health risks. Most antibiotics are unable to reach optimal therapeutic levels in joints and the central nervous system, leaving Borrelia to thrive in those hidden niches, resulting in infection recurrence and serious neurologic sequelae. Moreover, in case of neuroborreliosis), the treatment is extremely difficult due to low biodistribution of
antibiotics in brain. Neisserial meningitis typically sets very fast (1-2 days) and death can occur within 3-4 days (in case of toddlers and adolescents). Treatment is very difficult due to low biodistribution of antibiotics in the brain. Very high doses are required to achieve effect concentration of the antibiotics in the brain.
In case of Neisseria meningitidis, four non-cytotoxic dendrimers DDC18-4TA, lb, DD01e-8TA and MBola-8T showed a bactericidal effect. DD01e8TA and MBola-8T had MIC 50 pM, while lb and DDC18-4TA had MIC 6.25 pM. The minimum time required to kill N. meningitidis for lb was 3h.
Example 3. Hydrophobic chain
Further, it was tested how the hydrophobic chain affects the antibacterial activity of the dendrimers. In the present case, the dendrimer la, although at low generation, is endowed with strong antibacterial activity. The antibacterial activity of dendrimer 2, having no hydrophobic chain (see Fig. 6) was tested. Dendrimer 2, the structural analogue of la devoid of the hydrophobic chain has no antibacterial activity at all. This can be reasonably explained considering that the low -generation cationic dendrimer 2 alone is not sufficient to provide strong electrostatic interaction with the bacterial membrane for generating effective antibacterial activity. On the other hand, the presence of the long and hydrophobic chain C 18 in la, coupled with its amphiphilic character, is important for the observed antibacterial activity, as it leads to the formation of nano-assemblies for more effective and multivalent interaction with bacterial membrane via electrostatic interactions and, at the same time, via collective hydrophobic interactions between the alkyl chain of la and the hydrophobic region of bacterial membrane, hence leading to strong inhibition on bacterial growth.
In addition, the influence of the generation on the antibacterial activity was tested. Dendrimers of 1st and 2nd generation (Fig. IE (first generation, Figs. IE, IF and 1G, second generation) have been generated. It was previously reported that cationic dendrimers of high generations may disrupt bacterial membrane by inducing pore formation via cooperative electrostatic interaction between the cationic dendrimer terminals and the anionic bacterial membrane surface. Surprisingly it was now shown that dendrimers of low generations are also active as antibacterial agents. These dendrimers showed lower but still significant antibacterial activity as shown in Table 4.
Example 4. Encapsulation of known antibiotics using the dendrimers.
As la is able to self-assemble into stable nanomicelles, we explored its ability to encapsulate the antibiotics Azithromycin (AZM), Doxycycline (DOX) and Ciprofloxacin (CIP) and tested the antibacterial activity of the complex, and in particular the ability of the nanomicelles to deliver the antibiotics across biofilm barriers. Both AZM and CIP are broadspectrum and effective against planktonic bacteria but fail to show potent activity against biofilms of MRSA 1206. Remarkably, AZM and CIP (separately) were loaded in the nanomicelles formed by la with excellent encapsulation efficiencies of > 90 % as well as loading efficiencies of 44 %, 55% and 24 %, respectively. In addition, the co-constructed nanosystems AZM/la, DOX/la and CIP/la were more effective than the individual AZM, CIP, DOX and la. The significantly enhanced activity of AZM, DOX and CIP demonstrates not only the antibacterial activity of la, but also the carrier feature of la which has good penetrability in bacteria biofilm membrane, offering new dimensions to antibacterial therapy against drug resistance bacteria and bacteria within biofilm matrix.
In an additional experiment, the capacity of the dendrimer lb for encapsulation of the antibacterial drug DOX was assessed and showed Encapsulation efficiency of 90% and drug loading of 57%.
Further, doxycycline was encapsulated in DD01e-8TA to generate anti-borrelia nanoformulation (Borrelia bavariensis), whereas, ciprofloxacin was incorporated in lb to create anti-neis serial nanoformulation (Neisseria meningitidis).
DDole-8TA showed a synergistic anti-Borrelia effect with encapsulated doxycycline by reducing their individual MIC to > 8 times with a FICI value of < 0.5. Similarly, encapsulation of ciprofloxacin in lb showed a synergistic anti-Neisseria effect with a reduction in their individual MIC values by > 35 times for lb and > 104 time for ciprofloxacin with a FICI value of < 0.4.
When tested against MRSA, dendrimer la showed an additive effect with Ciprofloxacin with FICI >0.5 and additive to indifference effect with AZM, however, la showed synergistic effect with Doxycycline with FICI value of < 0.5.
FICI was calculated as follows (see e.g. Bellio et al., MethodsX. 2021; 8: 101543).
FICI ;;; MIC a combination ,-i- MIC. h combination
MIC alone MICS, alone
These data support that the antibiotic s/dendrimer nanoformulations were much more effective than the individual antibiotics and dendrimer alone, highlight a synergic effect for antibacterial activity using the amphiphilic dendrimer-based drug delivery systems.
In addition, the following encapsulated particles are formed. Particles of dendrimers having a structure of Formula II encapsulating erythromycin are formed. Particles of dendrimers having a structure of Formula II encapsulating vancomycin are formed. Particles of dendrimers having a structure of Formula II encapsulating cefuroxime are formed. In addition, the following encapsulated particles are formed. Particles of dendrimers having a structure of Formula IV encapsulating erythromycin are formed. Particles of dendrimers having a structure of Formula IV encapsulating vancomycin are formed. Particles of dendrimers having a structure of Formula IV encapsulating cefuroxime are formed. In addition, the following encapsulated particles are formed. Particles of dendrimers having a structure of Formula IV encapsulating azithromycin are formed. Particles of dendrimers having a structure of Formula IV encapsulating ciprofloxacin are formed. Particles of
dendrimers having a structure of Formula VI encapsulating erythromycin are formed. Particles of dendrimers having a structure of Formula VI encapsulating vancomycin are formed. Particles of dendrimers having a structure of Formula VI encapsulating cefuroxime are formed. In addition, the following encapsulated particles are formed. Particles of dendrimers having a structure of Formula VI encapsulating azithromycin are formed. Particles of dendrimers having a structure of Formula VI encapsulating ciprofloxacin are formed. Particles of dendrimers having a structure of Formula III encapsulating doxycycline are formed. Particles of dendrimers having a structure of Formula III encapsulating ciprofloxacin are formed. Particles of dendrimers having a structure of Formula III encapsulating erythromycin are formed. Particles of dendrimers having a structure of Formula III encapsulating vancomycin are formed. Particles of dendrimers having a structure of Formula III encapsulating cefuroxime are formed. In addition, the following encapsulated particles are formed. Particles of dendrimers having a structure of Formula III encapsulating azithromycin are formed. Particles of dendrimers having a structure of Formula III encapsulating ciprofloxacin are formed. Particles of dendrimers having a structure of Formula X encapsulating doxycycline are formed. Particles of dendrimers having a structure of Formula X encapsulating ciprofloxacin are formed. Particles of dendrimers having a structure of Formula X encapsulating erythromycin are formed. Particles of dendrimers having a structure of Formula X encapsulating vancomycin are formed. Particles of dendrimers having a structure of Formula X encapsulating cefuroxime are formed. In addition, the following encapsulated particles are formed. Particles of dendrimers having a structure of Formula X encapsulating azithromycin are formed. Particles of dendrimers having a structure of Formula X encapsulating ciprofloxacin are formed. In some examples, doxycycline is replaced by other tetracyclines minocycline, demeclocycline, oxy tetracycline, lymecycline or methacycline. In some examples, ciprofloxacin is replaced by other fluoroquinolones such as levofloxacin, levofloxacin, gatifloxacin, gatifloxacin or sparfloxacin. In some examples, azithromycin is replaced by other macrolides such as clarithromycin, dirithromycin, or roxithromycin. In some examples, particles of dendrimers having a structure as described above encapsulating a cephalosporin such as cefuroxime, cefpodoxime, cefotaxime, ceftriaxone or ceftazidime. Compositions comprising these particles are formulated and tested for their antibacterial activity.
In conclusion, amphiphilic dendrimers bearing distinct terminal functionalities were designed and synthesized and their antibacterial activity was evaluated. These dendrimers
are all capable to self-assemble spontaneously into small and stable supramolecular nanomicelles in water. Among them, the positively charged amine-terminated dendrimer la showed the most powerful activity against both Gram-positive and Gram-negative bacteria as well as drug-resistant bacteria and biofilm eradication, whereas the negatively charged carboxylic acid-terminated dendrimer Id was devoid of activity. Although the positively charged tertiary amine-terminated dendrimer lb was effective against the Gram-negative bacteria Escherichia coli, it had a much weaker effect on the other bacteria tested; surprisingly, lb has a good antibacterial activity against Neisseria meningitidis. Interestingly, the guanidine-terminated dendrimer 1c didn’t exhibit any notable antibacterial activity. The distinct antibacterial activity observed with these dendrimers can be ascribed to the different charge and charge density associated with the varying terminal functionalities, leading to variable interaction with the negatively charged bacterial membranes, thereby divergent antibacterial activity. Also, the self-assembling feature of the amphiphilic dendrimer la is responsible and decisive for its potent antibacterial activity, as the hydrophilic dendrimer counterpart without the alkyl chain has no activity at all. By virtue of the unique self-assembling character and strong interaction with bacterial membrane, la is endowed with excellent antibacterial activity. It is also to note that, compared to the reported dendrimers with antibacterial activity, our amphiphilic dendrimers presented in this work are of low generation and easy to synthesize. In addition, the amphiphilic dendrimer la is able to form nanomicelle and co-deliver the antibacterial agents for more effective activity to overcome antimicrobial resistance of biofilm, offering a new perspective to develop potent and effective antibacterial agent. Moreover, some of the nanoparticles of the dendrimer encapsulating antibacterial agents provided a synergistic antibacterial activity.
Examples 5
In vivo safety and antibacterial activity of la was further assessed in different mouse models. CD-I mice that were exposed to 5 mg/kg la show indistinguishable serum biochemistry and haematology from the control cohort exposed to sterile saline. Additionally, no la treatment-associated toxicity or inflammatory changes were observed in the histopathological analysis of major organs (heart, lungs, liver, spleen, kidneys) when compared to the saline control.
Pharmacokinetic analysis exploiting live imaging of Cyanine7.5-labeled la using an IVIS SpectrumCT Imaging system revealed that the compound was stable for more than 72 hours with strong accumulation in infected organs. Importantly, la (5 mg/kg, twice daily)
either outperformed or attained equal level of efficacy of commercially available antibiotics against ESKAPE pathogens, including acute pneumonia (5.05 log reduction compared to 4.63 log reduction by Tobramycin in lungs) and bacteraemia (2.99 log reduction compared to 2.16 log reduction by Tobramycin in spleens) models of infection by Pseudomonas aeruginosa; acute pneumonia (2.69 log reduction compared to 2.04 log reduction by Daptomycin in lungs) and bacteraemia (3.6 log reduction compared to 1.38 log reduction by Daptomycin in spleens) models of infection by MRS A; acute pneumonia (1.81 log reduction compared to 2.43 log reduction by Tigecycline in lungs) and bacteraemia (3.52 log reduction compared to 3.08 log reduction by Tigecycline in spleens) models of infection by Klebsiella pneumoniae; and immunosuppressed (neutropenic) soft tissue (thigh) infection by P. aeruginosa (4.17 log reduction compared to 4.88 log reduction by Tobramycin) and MRSA (4.47 log reduction compared to 4.95 log reduction by Daptomycin).
Finally, la (5 mg/kg, twice daily) showed great efficacy in a mouse model of bacteraemia mortality study. Mice infected with P. aeruginosa strain PAO1 and treated with saline showed 80% mortality. In contrast, no PAO1 -infected mice died in the la treated cohort. Collectively, our in vivo data indicate that la has strong safety, pharmacokinetics and efficacy in preclinical mouse models. In vivo antibacterial activity of lb and DDOle- 8TA (Formula IV and VI) are evaluated in mouse models of different infectious diseases.
Although the present invention has been described herein above by way of preferred embodiments thereof, it can be modified, without departing from the spirit and nature of the subject invention as defined in the appended claims
Claims
1. A pharmaceutical composition comprising, as an active agent, a dendrimer selected from an amine-terminated polyamidoamine dendrimer comprising a hydrophobic tail and bola- amphiphilic amine-terminated polyamidoamine dendrimer, for use in treating a pathogenic infection.
2. The pharmaceutical composition for use of claim 1 , wherein the dendrimer is selected from generation 2, 3 or 4 dendrimer comprising from 4 to 16 terminal amines.
3. The pharmaceutical composition for use according to claim 1 or 2, wherein the terminal amines are positively charged amines.
4. The pharmaceutical composition for use according to any one of claims 1 to 3, wherein the terminal amines are primary amines.
5. The pharmaceutical composition for use according to any one of claims 1 to 4, comprising, as an active agent, an amine-terminated polyamidoamine dendrimer comprising a hydrophobic tail.
6. The pharmaceutical composition for use according to claim 5, wherein the hydrophobic tail is a moiety selected from a C16-C32 alkyl and a C16-C32 alkenyl.
8. The pharmaceutical composition for use according to claim 7, wherein the hydrophobic tail is selected from a C16-C22 alkyl and a C16-C22 alkenyl.
H 10. The pharmaceutical composition for use according to claim 7, wherein (i) X is C18 o straight alkenyl; (ii) R is J^NX^X.NH2; or (iii) both (i) and (ii). H
11. The pharmaceutical composition for use according to any one of claims 8 to 10, wherein the alkenyl is a diene.
12. The pharmaceutical composition for use according to claim 1, wherein the dendrimer has a structure selected from a structure of Formula II, III, IV, V, VI, VII, VIII,
13. The pharmaceutical composition for use according to any one of claims 1 to 4, comprising, as an active agent, a bola-amphiphilic amine-terminated polyamidoamine dendrimer.
14. The pharmaceutical composition for use according to claim 13, wherein the bola- amphiphilic amine-terminated polyamidoamine dendrimer has a structure of Z-Y-Z, wherein:
Z has the structure of Formula I:
wherein R is selected from ■ ■> and any
combination thereof, and X is a moiety selected from C8-C16 alkyl, Cl l alkyl, C8-C16 alkenyl and C 11 alkenyl and Y is a linker.
15. The pharmaceutical composition for use according to claim 14, comprising a dendrimer having a structure selected from a structure of Formula XII, XIII, and XIV.
16. The pharmaceutical composition for use according to any one of claims 1 to 15, wherein the pathogenic infection is a bacterial infection.
17. The pharmaceutical composition for use according to claim 16, wherein the bacterial infection is caused by bacteria selected from Gram-positive and Gram-negative bacteria.
18. The pharmaceutical composition for use according to claim 17, wherein the bacterial infection is caused by bacteria selected from Pseudomonas, Klebsiella, Staphylococcus, Borrelia, Neisseria, and bacteria resistant to an antibiotic.
19. The pharmaceutical composition for use according to claim 18, wherein the bacterial infection is caused by bacteria selected from Pseudomonas aeruginosa, methicillin resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Staphylococcus aureus, BorreZz’a bavariensis and Neisseria meningitidis.
20. The pharmaceutical composition for use according to any one of claims 1 to 19, wherein the use comprises co-administering the pharmaceutical composition with an additional anti-pathogenic agent.
21. The pharmaceutical composition according to claim 20, wherein the pharmaceutical composition provides a synergistic anti-pathogenic activity.
22. The pharmaceutical composition for use according to claim 19 or 20, wherein the additional anti-pathogenic agent is an antibacterial agent.
23. The pharmaceutical composition for use according to claim 22, wherein the antibacterial agent is selected from doxycycline, azithromycin, ciprofloxacin, erythromycin, vancomycin and cefuroxime.
24. A pharmaceutical composition comprising a plurality of particles comprising a hydrophobic antipathogenic agent encapsulated within amine-terminated polyamidoamine dendrimers comprising a hydrophobic tail.
25. The pharmaceutical according to claim 24, wherein the dendrimers are selected from generation 1, 2, 3 or 4 dendrimers comprising from 4 to 16 terminal amines.
26. The pharmaceutical composition according to any one of claims 24 to 25, wherein the terminal amines are selected from primary amines and tertiary amines.
27. The pharmaceutical according to claim 24 or 25, wherein the amines are positively charged amine.
28. The pharmaceutical composition according to any one of claims 24 to 27, wherein the hydrophobic tail is a moiety selected from a C16-C32 alkyl and a C16-C32 alkenyl.
29. The pharmaceutical composition according to claim 28, wherein the dendrimer has a structure of formula I:
wherein R is selected from 2 and any
H H H combination thereof, and X is a moiety selected from C16-C32 alkyl and C16-C32 alkenyl.
30. The pharmaceutical composition according to claim 29, wherein: (i) X is a C 18 o straight alkyl, (ii) R is
, or (iii) both (i) and (ii).
H
32. The pharmaceutical composition according to claim 24, wherein the dendrimers have a structure selected from a structure of Formula II, III IV, V, VI, VII, VIII, IX, X and XI.
33. The pharmaceutical composition according to any one of claims 24 to 32, wherein the antipathogenic agent is an antibacterial agent.
34. The pharmaceutical composition according to claim 33, wherein the hydrophobic antibacterial agent is selected from doxycycline, azithromycin, ciprofloxacin, erythromycin, vancomycin and cefuroxime.
35. The pharmaceutical composition according to any one of claims 24 to 34, wherein the particles have a synergistic anti-pathogenic activity.
36. The pharmaceutical composition according to claim 35, wherein the particles have a synergistic antibacterial activity.
37. The pharmaceutical composition according to any one of claims 24 to 36, for use in treating an infection caused by a pathogen.
38. The pharmaceutical composition according to claim 37, wherein the pathogen is bacteria.
39. The pharmaceutical composition for use according to claim 38, wherein the bacterial infection is caused by bacteria selected from Gram-positive and Gram-negative bacteria.
40. The pharmaceutical composition for use according to claim 39, wherein the bacterial infection is caused by bacteria selected from Pseudomonas, Klebsiella, Staphylococcus, Borrelia and Neisseria.
41. The pharmaceutical composition for use according to claim 40, wherein the bacterial infection is caused by bacteria selected from Pseudomonas aeruginosa, MRSA, Klebsiella pneumoniae, Staphylococcus aureus, Borrelia bavariensis and Neisseria meningitidis.
42. The pharmaceutical composition for use according to claim 38, wherein the bacterial infection is caused by bacteria resistant to an antibiotic.
43. The pharmaceutical composition for use according to any one of claims 37 to 42, wherein the use comprises co-administering the pharmaceutical composition with an additional anti-pathogenic agent.
44. An amine-terminated polyamidoamine dendrimer, wherein the dendrimer comprises a hydrophobic tail comprising a C16-C32 alkenyl.
45. The dendrimer of claim 44, wherein the dendrimer is selected from generation 2, 3, 4 and 5 dendrimer.
46. The dendrimer of claim 44 or 45, wherein the dendrimer comprises from 4 to 32 terminal amines.
47. The dendrimer according to any one of claims 44 to 46, wherein the terminal amines are primary amines.
48. The dendrimer according to any one of claims 44 to 47 wherein the terminal amines are positively charged amines.
49. The dendrimer according to any one of claims 44 to 48, wherein the hydrophobic tail comprises two or more double bonds.
50. The dendrimer according to claim 44, having a structure of Formula I:
51. The dendrimer according to any one of claims 44 to 50, wherein the hydrophobic tail is selected from a C16-C22 alkenyl.
52. The dendrimer according to claim 50 or 51, wherein (i) X is C18 straight alkenyl; (ii)
53. The dendrimer according to any one of claims 44 or 52, wherein the alkenyl is a diene.
54. The dendrimer according to claim 53, wherein the diene is a conjugated diene.
55. The dendrimer according to claim 44, wherein the dendrimer has a structure selected from a structure of Formula V, VI, VII, and VIII:
56. Particles comprising a plurality of dendrimers according to any one of claims 44 to 55.
57. The particles according to claim 56, encapsulating a biologically active agent.
58. The particles according to claim 57, wherein the biologically active agent is selected from a nucleic acid and an active agent.
59. The particles according to claim 58, wherein the nucleic acid is selected from DNA and RNA and the active agent is an anti-pathogenic agent.
60. The particles according to claim 59, wherein the anti-pathogenic agent is an antibacterial agent.
61. A composition comprising a plurality of dendrimers according to any one of claims
44 to 55 or a plurality of particles according to any one of claims 56 to 60, and a carrier.
62. The composition according to claim 61 , wherein the composition is a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
63. The composition according to claim 62, for use in treating a pathogenic infection.
64. The composition for use according to claim 62, wherein the pathogenic infection is a bacterial infection.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263343121P | 2022-05-18 | 2022-05-18 | |
US63/343,121 | 2022-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023223317A1 true WO2023223317A1 (en) | 2023-11-23 |
Family
ID=86732214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2023/050499 WO2023223317A1 (en) | 2022-05-18 | 2023-05-15 | Self-assembling dendrimers and antibacterial uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023223317A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3473249A1 (en) * | 2010-03-31 | 2019-04-24 | Wayne State University | Crosslinkable dendrimers |
WO2021257723A1 (en) * | 2020-06-18 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for new therapeutic agents including guanidinium-presenting dendrimers and branched structures |
-
2023
- 2023-05-15 WO PCT/IL2023/050499 patent/WO2023223317A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3473249A1 (en) * | 2010-03-31 | 2019-04-24 | Wayne State University | Crosslinkable dendrimers |
WO2021257723A1 (en) * | 2020-06-18 | 2021-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for new therapeutic agents including guanidinium-presenting dendrimers and branched structures |
Non-Patent Citations (19)
Title |
---|
ALFEI ET AL., NANOMATERIALS, vol. 10, no. 10, 2020, pages 2022 |
ALFEICAVIGLIA, PHARMACEUTICS, vol. 14, no. 10, 2022, pages 2016 |
BELLIO ET AL., METHODSX, vol. 8, 2021, pages 101543 |
CASTONGUAY A ET AL., NEW J. CHEM., vol. 36, 2012, pages 199 - 204 |
CASTONGUAY ANNIE ET AL: "Dendrimers as bactericides", NEW JOURNAL OF CHEMISTRY, vol. 36, no. 2, 1 January 2012 (2012-01-01), GB, pages 199 - 204, XP093065378, ISSN: 1144-0546, DOI: 10.1039/C1NJ20481E * |
CHEN ET AL.: "Gene Silencing", SMALL, vol. 12, 2016, pages 3667 - 76 |
HAYOUKA ET AL., J AM CHEM SOC., vol. 135, no. 32, 2013, pages 11748 - 51 |
HINMAN SAMUEL S. ET AL: "Mix and Match: Coassembly of Amphiphilic Dendrimers and Phospholipids Creates Robust, Modular, and Controllable Interfaces", APPLIED MATERIALS & INTERFACES, vol. 9, no. 1, 22 December 2016 (2016-12-22), US, pages 1029 - 1035, XP093065345, ISSN: 1944-8244, DOI: 10.1021/acsami.6b11556 * |
KANNAN ET AL., ACS APPL BIO MATER, vol. 2, 2019, pages 3212 - 24 |
L. ZHANG ET AL: "Development of Nanoparticles for Antimicrobial Drug Delivery", CURRENT MEDICINAL CHEMISTRY, vol. 17, no. 6, 1 February 2010 (2010-02-01), NL, pages 585 - 594, XP055516428, ISSN: 0929-8673, DOI: 10.2174/092986710790416290 * |
LIU XIAOXUAN ET AL: "Promoting siRNA delivery via enhanced cellular uptake using an arginine-decorated amphiphilic dendrimer", NANOSCALE, vol. 7, no. 9, 1 January 2015 (2015-01-01), United Kingdom, pages 3867 - 3875, XP093065337, ISSN: 2040-3364, DOI: 10.1039/C4NR04759A * |
LYU ET AL.: "Dendrimer Chemistry: Synthetic Approaches Towards Complex Architectures", 2020, ROYAL SOCIETY CHEMISTRY, pages: 85 - 113 |
MEYERS ET AL., J AM CHEM SOC, vol. 130, 2008, pages 14444 - 5 |
MINTZER MA ET AL., MOL PHARM., vol. 9, no. 3, 2012, pages 342 - 54 |
TIANZHU YU ET AL: "An Amphiphilic Dendrimer for Effective Delivery of Small Interfering RNA and Gene Silencing In Vitro and In Vivo", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE, HOBOKEN, USA, vol. 51, no. 34, 24 July 2012 (2012-07-24), pages 8478 - 8484, XP072070928, ISSN: 1433-7851, DOI: 10.1002/ANIE.201203920 * |
XIAOXUAN LIU ET AL: "A Fluorinated Bola-Amphiphilic Dendrimer for On-Demand Delivery of siRNA, via Specific Response to Reactive Oxygen Species", ADVANCED FUNCTIONAL MATERIALS, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 26, no. 47, 26 October 2016 (2016-10-26), pages 8594 - 8603, XP072413465, ISSN: 1616-301X, DOI: 10.1002/ADFM.201604192 * |
XIAOYAN XUE ET AL: "Amino-Terminated Generation 2 Poly(amidoamine) Dendrimer as a Potential Broad-Spectrum, Nonresistance-Inducing Antibacterial Agent", AAPS JOURNAL, AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS, US, vol. 15, no. 1, 8 November 2012 (2012-11-08), pages 132 - 142, XP035156237, ISSN: 1550-7416, DOI: 10.1208/S12248-012-9416-8 * |
YU ET AL., ANGEW CHEM INT ED ENGL., vol. 51, no. 34, 20 August 2012 (2012-08-20), pages 8478 - 84 |
ZHANG WENZHENG ET AL: "Bola-Amphiphilic Glycodendrimers: New Carbohydrate-Mimicking Scaffolds to Target Carbohydrate-Binding Proteins", CHEMISTRY - A EUROPEAN JOURNAL, vol. 28, no. 58, 26 August 2022 (2022-08-26), DE, XP093066477, ISSN: 0947-6539, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/chem.202201400> DOI: 10.1002/chem.202201400 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Nanocarriers with conjugated antimicrobials to eradicate pathogenic biofilms evaluated in murine in vivo and human ex vivo infection models | |
Singh et al. | Dual bioresponsive antibiotic and quorum sensing inhibitor combination nanoparticles for treatment of Pseudomonas aeruginosa biofilms in vitro and ex vivo | |
Yang et al. | Eradicating intracellular MRSA via targeted delivery of lysostaphin and vancomycin with mannose-modified exosomes | |
US9180132B2 (en) | Antimicrobial cationic steroids and methods of use | |
KR20110028372A (en) | Functional micelles for hard tissue targeted delivery of chemicals | |
US10967065B2 (en) | Compounds for treating biofilm infection | |
JP2001523723A (en) | Phospholipids with antimicrobial activity in the presence or absence of antimicrobial agents | |
JP6994941B2 (en) | Antisense antibacterial compounds and methods | |
Guo et al. | Development of polycationic micelles as an efficient delivery system of antibiotics for overcoming the biological barriers to reverse multidrug resistance in Escherichia coli | |
WO2018081845A1 (en) | Antibacterial compositions and methods | |
US20130281424A1 (en) | Anti-bacterial siderophore-aminopenicillin conjugates | |
Peng et al. | Glutathione-responsive multifunctional nanoparticles based on mannose-modified pillar [5] arene for targeted antibiotic delivery against intracellular methicillin-resistant S. aureus | |
US20170095502A1 (en) | Antimicrobial Metal-Binding Polymers | |
CN112755174B (en) | Polymyxin derivatives, preparation method and application thereof | |
US10759740B2 (en) | Antibacterial agents | |
JP6051305B2 (en) | Pharmaceutical composition for promoting protoporphyrin IX production | |
WO2023223317A1 (en) | Self-assembling dendrimers and antibacterial uses thereof | |
JP2001508416A (en) | Composition comprising a lipophilic oligosaccharide antibiotic and albumin | |
JP2021532192A (en) | Therapeutic nanoparticles by coacervate complexing and their use for treating bacteria | |
JP6590924B2 (en) | Synergistic composition for treating microbial infection | |
US20120172289A1 (en) | Multifunctional glycopeptide antibiotic derivatives for fluorescent imaging and photoactive antimicrobial therapy | |
Tülü et al. | Dendrimers as antibacterial agents | |
US20180111963A1 (en) | Anti-microbial supramolecular structures | |
WO2019014389A1 (en) | Stimuli-responsive polysaccharide antimicrobial agents | |
Yang et al. | Progress of stimulus responsive nanosystems for targeting treatment of bacterial infectious diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23729520 Country of ref document: EP Kind code of ref document: A1 |